{  
   "name":"Claim Categories",
   "children":[  
      {  
         "name":"Antibody",
         "color":"green",
         "children":[  
            {  
               "name":"Sequence",
               "color":"green",
               "children":[  
                  {  
                     "name":"Variable Region",
                     "color":"green",
                     "claimReason":"“... with a light chain variable region (LCVR) having a CDR3 domain comprising the amino acid sequence of SEQ ID NO: 3 ...”",
                     "indClaim":"<p>[IC]</p>12. An isolated human antibody, or an antigen-binding portion thereof, with a light chain variable region (LCVR) having a CDR3 domain comprising the amino acid sequence of SEQ ID NO: 3, or modified from SEQ ID NO: 3 by a single alanine substitution at position 1, 4, 5, 7 or 8, and with a heavy chain variable region (HCVR) having a CDR3 domain comprising the amino acid sequence of SEQ ID NO: 4, or modified from SEQ ID NO: 4 by a single alanine substitution at position 2, 3, 4, 5, 6, 8, 9, 10 or 11.",
                     "depClaim":"<p>[DC]</p>13. The isolated human antibody, or an antigen-binding portion thereof, of claim 12, wherein the LCVR further has a CDR2 domain comprising the amino acid sequence of SEQ ID NO: 5 and the HCVR further has a CDR2 domain comprising the amino acid sequence of SEQ ID NO: 6. <p>[DC]</p>14. The isolated human antibody, or an antigen-binding portion thereof, of claim 13, wherein the LCVR further has CDR1 domain comprising the amino acid sequence of SEQ ID NO: 7 and the HCVR has a CDR1 domain comprising the amino acid sequence of SEQ ID NO: 8.",
                     "source":"<p>Source:</p> US6090382A, Abott Biotech Company: Humira® Product"
                  },
                  {  
                     "name":"Full Length",
                     "color":"green",
                     "claimReason":"“… comprising a heavy chain comprising ... and a light chain comprising …”",
                     "indClaim":"<p>[IC]</p> 11. An isolated antibody comprising a heavy chain comprising amino acid residues 20 to 446 of SEQ ID NO: 31 and a light chain comprising amino acid residues of 20-237 of SEQ ID NO: 36.",
                     "depClaim":"<p>[DC]</p> None",
                     "source":"<p>Source:</p> US8354509B2, Merck & Co Company: Keytruda® Product"
                  },
                  {  
                     "name":"Nano Bodies",
                     "color":"green"
                  },
                  {  
                     "name":"Constant Region",
                     "color":"green",
                     "claimReason":"“... an IgG1 heavy chain constant ...”",
                     "indClaim":"<p>[IC]</p> 15. An isolated human antibody, or an antigen binding portion thereof, with a light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO: 1 and a heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO: 2.",
                     "depClaim":"<p>[DC]</p> 16. The isolated human antibody of claim 15, which has an IgG1 heavy chain constant region.<p>[DC]</p> 17. The isolated human antibody of claim 15, which has an IgG4 heavy chain constant region.<p>[DC]</p> 18. The isolated human antibody of claim 15, which is a Fab fragment.<p>[DC]</p> 19. The isolated human antibody of claim 15, which is a single chain Fv fragment.",
                     "source":"<p>Source:</p> US6090382A, Abott Biotech Company: Humira® Product"
                  }
               ]
            },
            {  
               "name":"Bi-Specific",
               "color":"green",
               "children":[  
                  {  
                     "name":"Normal",
                     "color":"green"
                  },
                  {  
                     "name":"Single Chain",
                     "color":"green",
                     "claimReason":"“… single-chain multi-functional polypeptide comprising …”",
                     "indClaim":"<p>[IC]</p> 1. A single-chain multi-functional polypeptide comprising: <p>(a)</p> a first domain comprising a binding-site of an antibody or an immunoglobulin chain thereof specifically recognizing the CD19 antigen. <p>(b)</p> a second domain comprising a binding site of an antibody or an immunoglobulin chain thereof recognizing the human CD3 antigen, wherein said domains are arranged in the order V L CD19-VHCD19-VHCD3-VLCD3.",
                     "depClaim":"<p>[DC]</p> 2. The polypeptide of claim 1, wherein said two domains are connected by a polypeptide linker.<p>[DC]</p> 3. The polypeptide of claim 1, wherein said first and/or second domain correspond to a VH and VL region from a natural antibody.<p>[DC]</p> 4. The polypeptide of claim 1, wherein said antibody is monoclonal antibody, synthetic antibody, or humanized antibody.<p>[DC]</p> 5. The polypeptide of claim 4, wherein at least one of said domains is a single-chain fragment of the variable region of the antibody.<p>[DC]</p> 6. The polypeptide of claim 2, wherein said polypeptide linker comprises a plurality of glycine, alanine, serine residues or combinations thereof.<p>[DC]</p> 7. The polypeptide of claim 2, wherein said polypeptide linker comprises a plurality of consecutive copies of an amino acid sequence.<p>[DC]</p> 8. The polypeptide of claim 2, wherein said polypeptide linker comprises 1 to 5 amino acid residues.<p>[DC]</p> 9. The polypeptide of claim 8, wherein said polypeptide linker comprises the amino acid sequence Gly Gly Gly Gly Ser.<p>[DC]</p> 10. The polypeptide of claim 1, wherein <p>(a)</p> said binding site of the first domain has an affinity of at least about 10 -7 M; and/or<p>(b)</p> said binding site of the second domain has an affinity of less than about 10 -7 M.<p>[DC]</p> 11. The polypeptide of claim 1, wherein said polypeptide is a bispecific single-chain antibody.<p>[DC]</p> 12. The polypeptide of claim 1, comprising at least one further domain.<p>[DC]</p> 13. A The polypeptide of claim 12, wherein said further domain is linked by covalent or noncovalent bonds.<p>[DC]</p> 14. The polypeptide of claim 12, wherein said at least one further domain comprises an effector molecule having a conformation suitable for biological activity, capable of sequestering an ion or selective binding to a solid support or to a preselected determinant.<p>[DC]</p> 15. A method for the preparation of a single-chain multi-functional polypeptide comprising: cultivating a cell transfected with a polynucleotide which upon expression encodes the singlechain multi-functional polypeptide of claim 1; and isolating said polypeptide from the cell.",
                     "source":"<p>Source:</p> US7112324B1, Amgen Company: Blincyto® Product"
                  }
               ]
            },
            {  
               "name":"Function",
               "color":"green",
               "children":[  
                  {  
                     "name":"Affinity",
                     "color":"green",
                     "claimReason":"“… dissociates from human TNF with a Kd of 1×10-8 M or less and a Koff rate constant of 1×10-3 s-1 or less …”",
                     "indClaim":"<p>[IC]</p> 1. An isolated human antibody, or an antigen-binding portion thereof, that dissociates from human TNF with a Kd of 1×10-8 M or less and a Koff rate constant of 1×10-3 s-1 or less, both determined by surface plasmon resonance, and neutralizes human TNF cytotoxicity in a standard in vitro L929 assay with an IC50 of 1×10-7 M or less.",
                     "depClaim":"<p>[DC]</p> 2. The isolated human antibody, or antigen-binding portion thereof, of claim 1, which dissociates from human TNF with a Koff rate constant of 5×10-4 s-1 or less.<p>[DC]</p> 3. The isolated human antibody, or antigen-binding portion thereof, of claim 1, which dissociates from human TNF with a Koff rate constant of 1×10-4 s-1 or less.<p>[DC]</p> 4. The isolated human antibody, or antigen-binding portion thereof, of claim 1, which neutralizes human TNF cytotoxicity in a standard in vitro L929 assay with an IC50 of 1×10-8 M or less.<p>[DC]</p> 5. The isolated human antibody, or antigen-binding portion thereof, of claim 1, which neutralizes human TNF cytotoxicity in a standard in vitro L929 assay with an IC50 of 1×10-9 M or less.<p>[DC]</p> 6. The isolated human antibody, or antigen-binding portion thereof, of claim 1, which neutralizes human TNF cytotoxicity in a standard in vitro L929 assay with an IC50 of 1×10-10 M or less.<p>[DC]</p> 7. The isolated human antibody, or antigen-binding portion thereof, of claim 1, which is a recombinant antibody, or antigen-binding portion thereof.<p>[DC]</p> 8. The isolated human antibody, or antigen-binding portion thereof, of claim 1, which inhibits human TNF-induced expression of ELAM-1 on human umbilical vein endothelial cells.",
                     "source":"<p>Source:</p> US6090382A, Abott Biotech Company: Humira® Product"
                  },
                  {  
                     "name":"Cytotoxicity",
                     "color":"green",
                     "claimReason":"“… and neutralizes human TNF cytotoxicity in a standard in vitro L929 assay with an IC50 of 1×107 M or less …”",
                     "indClaim":"<p>[IC]</p> 54. A pharmaceutical composition comprising an isolated human antibody, or antigen-binding portion thereof, which dissociates from human TNF with a Kd of 1×108 M or less and a Koff rate constant of 1×103 s1 or less, both determined by surface plasmon resonance, and neutralizes human TNF cytotoxicity in a standard in vitro L929 assay with an IC50 of 1×107 M or less, and a pharmaceutically acceptable carrier, wherein the composition has a form selected from the group consisting of a liquid, a semi-solid dosage form, a solid dosage form, a dispersion, a suspension, a tablet, a pill, a powder, a liposome, and a suppository.",
                     "depClaim":"<p>[DC]</p> None",
                     "source":"<p>Source:</p> US8414894B2, Abott Biotech Company: Humira® Product"
                  },
                  {  
                     "name":"Binding Inhibition",
                     "color":"green",
                     "claimReason":"“… interacts with a human osteoprotegerin ligand (OPGL) and inhibits binding of human OPGL to an osteoclast differentiation and activation receptor (ODAR) …”",
                     "indClaim":"<p>[IC]</p> 1. A method of treating bone loss in a patient, comprising administering an antibody comprising a heavy chain and a light chain, wherein the heavy chain comprises CDR1, CDR2, and CDR3 of SEQ ID NO: 13 and the light chain comprises CDR1, CDR2, and CDR3 of SEQ ID NO: 14, wherein the heavy chain and light chain form an antibody that interacts with a human osteoprotegerin ligand (OPGL) and inhibits binding of human OPGL to an osteoclast differentiation and activation receptor (ODAR).",
                     "depClaim":"<p>[DC]</p> 2. The method of claim 1, wherein: <p>a)</p> the heavy chain comprises an amino acid sequence having at least 95% identity to SEQ ID NO: 13; and <p>b)</p> the light chain comprises an amino acid sequence having at least 95% identity to SEQ ID NO: 14.<p>[DC]</p> 3. The method of claim 2, wherein the heavy chain comprises an amino acid sequence having at least 99% identity to SEQ ID NO: 13 and the light chain comprises an amino acid sequence having at least 99% identity to SEQ ID NO: 14.",
                     "source":"<p>Source:</p> US8409578B2, Amgen Company: Prolia® Product"
                  },
                  {  
                     "name":"Epitope",
                     "color":"green",
                     "claimReason":"“… antibody which binds to epitope 4D5 within the ErbB2 extracellular domain sequence …”",
                     "indClaim":"<p>[IC]</p> 1. A method for the treatment of a human patient with a malignant progressing tumor or cancer characterized by overexpression of ErbB2 receptor, comprising administering a combination of an intact antibody which binds to epitope 4D5 within the ErbB2 extracellular domain sequence and a taxoid, in the absence of an anthracycline derivative, to the human patient in an amount effective to extend the time to disease progression in said human patient, without increase in overall severe adverse events.",
                     "depClaim":"<p>[DC]</p> 2. The method of claim 1 wherein said patient has a malignant tumor.<p>[DC]</p> 3. The method of claim 1 wherein said patient has cancer.<p>[DC]</p> 4. The method of claim 3 wherein said cancer is selected from the group consisting of breast cancer, squamous cell cancer, small-cell lung cancer, non-small cell lung cancer, gastrointestinal cancer, pancreatic cancer, glioblastoma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, hepatoma, colon cancer, colorectal cancer, endometrial carcinoma, salivary gland carcinoma, kidney cancer, liver cancer, prostate cancer, vulval cancer, thyroid cancer, hepatic carcinoma and various types of head and neck cancer.<p>[DC]</p> 5. The method of claim 4 wherein said cancer is breast cancer.<p>[DC]</p> 6. The method of claim 5 wherein said cancer is metastatic breast carcinoma.<p>[DC]</p> 7. The method of claim 1 wherein said antibody is a humanized 4D5 anti-ErbB2 antibody.<p>[DC]</p> 8. The method of claim 1 wherein said taxoid is paclitaxel.<p>[DC]</p> 9. The method of claim 8 wherein the effective amount of said combination is lower than the sum of the effective amounts of said anti-ErbB2 antibody and said taxoid, when administered individually, as single agents.<p>[DC]</p> 10. The method of claim 1 wherein efficacy is further measured by determining the response rate.",
                     "source":"<p>Source:</p> US7846441B1, Genentech Company: Herceptin® Product"
                  }
               ]
            },
            {  
               "name":"Properties",
               "color":"green",
               "children":[  
                  {  
                     "name":"HPLC Properties",
                     "color":"green",
                     "claimReason":"“… wherein the acidic species of adalimumab correspond to the peaks that elute earlier than the main peak in a WCX-10 HPLC chromatogram of adalimumab …”",
                     "indClaim":"<p>[IC]</p> 1. A composition comprising adalimumab, wherein the composition comprises less than 10% total acidic species of adalimumab, wherein the acidic species of adalimumab correspond to the peaks that elute earlier than the main peak in a WCX-10 HPLC chromatogram of adalimumab, wherein the WCX-10 HPLC chromatogram is generated using a first mobile phase of 10 mM Sodium Phosphate dibasic (pH 7.5) and a second mobile phase of 10 mM Sodium Phosphate dibasic, 500 mM Sodium Chloride (pH 5.5), and wherein the WCX-10 HPLC chromatogram is generated using detection at 280 nm.",
                     "depClaim":"<p>[DC]</p> 2. The composition of claim 1, wherein the acidic species of adalimumab comprise a first acidic region (AR1) and a second acidic region (AR2).<p>[DC]</p> 3. The composition of claim 1, wherein the composition comprises less than 3.8% total acidic species of adalimumab.<p>[DC]</p> 4. The composition of claim 2, wherein the composition comprises 0.8% AR1 and 3.0% AR2.<p>[DC]</p> 5. The composition of claim 1, wherein the composition comprises less than 2.4% total acidic species of adalimumab.<p>[DC]</p> 6. The composition of claim 2, wherein the composition comprises 0.2% AR1 and 2.2% AR2.<p>[DC]</p> 7. The composition of claim 1, wherein the composition comprises 4.7%-8.3% total acidic species of adalimumab.<p>[DC]</p> 8. The composition of claim 7, wherein the composition comprises 4.7% total acidic species of adalimumab.<p>[DC]</p> 9. The composition of claim 7, wherein the composition comprises 5.0% total acidic species of adalimumab.<p>[DC]</p> 10. The composition of claim 7, wherein the composition comprises 5.8% total acidic species of adalimumab.<p>[DC]</p> 11. The composition of claim 7, wherein the composition comprises 6.1% total acidic species of adalimumab.<p>[DC]</p> 12. The composition of claim 7, wherein the composition comprises 6.4% total acidic species of adalimumab.<p>[DC]</p> 13. The composition of claim 7, wherein the composition comprises 8.1% total acidic species of adalimumab.<p>[DC]</p> 14. The composition of claim 7, wherein the composition comprises 8.3% total acidic species of adalimumab.<p>[DC]</p> 15. The composition of claim 2, wherein the composition comprises 0.8%-1.4% AR1.<p>[DC]</p> 16. The composition of claim 2, wherein the composition comprises 3%-9% AR2.17. The composition of claim 2, wherein the composition comprises 0.8% AR1 and 6.4% AR2.<p>[DC]</p> 18. The composition of claim 2, wherein the composition comprises 0.9% AR1 and 9% AR2.<p>[DC]</p> 19. The composition of claim 2, wherein the composition comprises 1.2% AR1 and 7.7% AR2.<p>[DC]</p> 20. The composition of claim 2, wherein the composition comprises 1.2% AR1 and 8.2% AR2.<p>[DC]</p> 21. The composition of claim 2, wherein the composition comprises 1.4% AR1 and 8.4% AR2.<p>[DC]</p> 22. The composition of claim 2, wherein the composition comprises 1.4% AR1 and 8.6% AR2.<p>[DC]</p> 23. The composition of claim 1, wherein the composition further comprises a pharmaceutically acceptable carrier.",
                     "source":"<p>Source:</p> US9334319B2, Abott Biotech Company: Humira® Product"
                  },
                  {  
                     "name":"Residue",
                     "color":"green",
                     "claimReason":"“… lysine variant species …”",
                     "indClaim":"<p>[IC]</p> 7. A composition comprising a human anti-TNF antibody, wherein the sum of the lysine variant species having one C-terminal lysine (Lys 1) and the lysine variant species having two C-terminal lysines (Lys 2) in said composition is greater than 35%, wherein the lysine variant species include the main peak and peaks that elute at a relative residence time later than the main peak, as detected using weak cation-exchange chromatography, and wherein the human anti-TNF antibody comprises a light chain variable region (LCVR) having a CDR1 domain comprising the amino acid sequence of SEQ ID NO:7, a CDR2 domain comprising the amino acid sequence of SEQ ID NO:5, and a CDR3 domain comprising the amino acid sequence of SEQ ID NO:3; and a heavy chain variable region (HCVR) having a CDR1 domain comprising the amino acid sequence of SEQ ID NO:8, a CDR2 domain comprising the amino acid sequence of SEQ ID NO:6, and a CDR3 domain comprising the amino acid sequence of SEQ ID NO:4.",
                     "depClaim":"<p>[DC]</p> 8. The composition of claim 7, wherein said human anti-TNF antibody is adalimumab.<p>[DC]</p> 9. The composition of claim 8, wherein the sum of the lysine variant species having one C-terminal lysine (Lys 1) and the lysine variant species having two C-terminal lysines (Lys 2) in said composition is greater than 40%.<p>[DC]</p> 10. The composition of claim 8, wherein the sum of the lysine variant species having one Cterminal lysine (Lys 1) and the lysine variant species having two C-terminal lysines (Lys 2) in said composition is 40-50%.<p>[DC]</p> 11. The composition of claim 8, wherein the sum of the lysine variant species having one Cterminal lysine (Lys 1) and the lysine variant species having two C-terminal lysines (Lys 2) in said composition is greater than 50%.<p>[DC]</p> 12. The composition of claim 8, wherein greater than 25% of the lysine variant species in said composition have one C-terminal lysine (Lys 1).<p>[DC]</p> 13. The composition of claim 8, wherein greater than 30% of the lysine variant species in said composition have one C-terminal lysine (Lys 1).<p>[DC]</p> 14. The composition of claim 7, wherein said composition is lyophilized.<p>[DC]</p> 15. A pharmaceutical formulation comprising the composition of claim 1 and a pharmaceutically acceptable carrier.<p>[DC]</p> 16. A pharmaceutical formulation comprising the composition of claim 7 and a pharmaceutically acceptable carrier.",
                     "source":"<p>Source:</p> US9181337B2, Abott Biotech Company: Humira® Product"
                  },
                  {  
                     "name":"Other",
                     "color":"green",
                     "claimReason":"“… mediates specific cell lysis of SK-BR-3 calls in the presence of IL-2 activated human …”",
                     "indClaim":"<p>[IC]</p> 15. A humanized variant of a non-human parent antibody, wherein the humanized variant comprises non-human Complementarity Determining Region (CDR) amino acid residues and human Framework Region (FR) amino acid residues, and: <p>(a)</p> binds the HER2 receptor with an affinity of about 4.7 nM Kd or better affinity: <p>(b)</p> mediates specific cell lysis of SK-BR-3 calls in the presence of IL-2 activated human peripheral blood lymphocytes at least about four fold more effectively than the non-human parent antibody; and <p>(c)</p> mediates Antibody Dependent Cellular Cytotoxicity (ADCC) selective for cell types which overexpress p185HER2 at least about two fold more effectively than for cell types which express low levels of p185HER2.",
                     "depClaim":"<p>[DC]</p> 16. The humanized variant of claim 15 which binds the HER2 receptor with an affinity of about 0.82 nM Kd or better affinity.<p>[DC]</p> 17. The humanized variant of claim 16 which binds the HER2 receptor with an affinity of about 0.10 nM Kd.<p>[DC]</p> 18. The humanized variant of claim 15 which inhibits proliferation of SK-BR-3 cells incubated for 96 hr with the antibody.<p>[DC]</p> 19. The humanized variant of claim 18 wherein the antibody inhibits proliferation of SK-BR-3 cells to about 66% of untreated control or greater inhibition.",
                     "source":"<p>Source:</p> US6054297A, Genentech Company: Avastin® Product"
                  }
               ]
            },
            {  
               "name":"Modified Antibody",
               "color":"green",
               "claimReason":"“… the main species HER2 antibody comprising an amino-terminal leader extension …”",
               "indClaim":"<p>[IC]</p> 1. A composition comprising: <p>(a)</p> a main species HER2 antibody that binds to domain II of HER2 and comprises the variable light amino acid sequence in SEQ ID No. 3 and the variable heavy amino acid sequence in SEQ ID No. 4, and <p>(b)</p> the main species HER2 antibody comprising an amino-terminal leader extension, wherein the amino-terminal leader extension comprises VHS-, wherein from 5% to about 15% of the antibody molecules in the composition comprise an aminoterminal leader extension, as quantified by cation exchange analysis.",
               "depClaim":"<p>[DC]</p> 2. The composition of claim 1 wherein the amino-terminal leader extension is on a light chain of the antibody comprising the VHS- extension.<p>[DC]</p> 3. The composition of claim 2 wherein the amino-terminal leader extension is on one or two light chains of the antibody comprising the VHS- extension.<p>[DC]</p> 4. The composition of claim 1 wherein the main species HER2 antibody and the antibody comprising the VHS- extension are both intact antibodies.<p>[DC]</p> 5. The composition of claim 1 wherein the main species HER2 antibody comprises the light chain amino acid sequence in SEQ ID No. 15 and the heavy chain amino acid sequence in SEQ ID No. 16.<p>[DC]</p> 6. The composition of claim 5 further comprising: <p>(a)</p> the main species HER2 antibody comprising a C-terminal lysine residue on one or both heavy chains thereof, <p>(b)</p> a deamidated main species HER2 antibody wherein Asn-386 and/or Asn-391 on one or two heavy chains of the main species HER2 antibody are deamidated, and <p>(c)</p> the main species HER2 antibody with one or more oxidized methionine residues at met-254 of SEQ ID No.16.<p>[DC]</p> 7. The composition of claim 1 wherein the amino-terminal leader extension consists of VHS-.<p>[DC]</p> 8. The composition of claim 1 further comprising a glycosylation variant of the main species HER2 antibody, wherein the glycosylation variant is selected from the group consisting of: <p>(a)</p> the main species HER2 antibody comprising a G1 or G2 oligosaccharide structure attached to an Fc region thereof, <p>(b)</p> the main species HER2 antibody comprising a carbohydrate moiety attached to a light chain thereof, <p>(c)</p> the main species HER2 antibody comprising a non-glycosylated heavy chain, and <p>(d)</p> the main species HER2 antibody with a sialidated oligosaccharide structure attached to an Fc region thereof.<p>[DC]</p> 9. The composition of claim 1 wherein the main species antibody binds to the junction between domains I, II and III of HER2.<p>[DC]</p> 10. A pharmaceutical formulation comprising the composition of claim 1 in a pharmaceutically acceptable carrier.<p>[DC]</p> 11. The pharmaceutical formulation of claim 10 which is sterile.",
               "source":"<p>Source:</p> US7560111B2, Genentech Company: Perjeta® Product"
            },
            {  
               "name":"By Sugar",
               "color":"green",
               "claimReason":"“…  N-linked oligosaccharides present on said adalimumab are of a galactose-containing fucosylated biantennary oligosaccharide form (sum of NA1F+NA2F) …”",
               "indClaim":"<p>[IC]</p> 1. A composition comprising adalimumab, wherein more than 25% of the total N-linked oligosaccharides present on said adalimumab are of a galactose-containing fucosylated biantennary oligosaccharide form (sum of NA1F+NA2F).",
               "depClaim":"<p>[DC]</p> 2. The composition of claim 1, wherein 26-40% of the total N-linked oligosaccharides present on said adalimumab are of a galactose-containing fucosylated biantennary oligosaccharide form (sum of NA1F+NA2F).<p>[DC]</p> 3. The composition of claim 1, wherein 35-44% of the total N-linked oligosaccharides present on said adalimumab are of a galactose-containing fucosylated biantennary oligosaccharide form (sum of NA1F+NA2F).<p>[DC]</p> 4. The composition of claim 1, wherein 30-40% of the total N-linked oligosaccharides present on said adalimumab are of a galactose-containing fucosylated biantennary oligosaccharide form (sum of NA1F+NA2F).<p>[DC]</p> 5. The composition of claim 1, wherein less than 70% of the total N-linked oligosaccharides present on said adalimumab are of an agalactosyl fucosylated biantennary oligosaccharide form (sum NGA2F+NGA2F-GlcNAc).<p>[DC]</p> 6. The composition of claim 5, wherein 49-69% of the total N-linked oligosaccharides present on said adalimumab are of an agalactosyl fucosylated biantennary oligosaccharide form (sum NGA2F+NGA2F-GlcNAc).<p>[DC]</p> 7. The composition of claim 5, wherein 55-65% of the total N-linked oligosaccharides present on said adalimumab are of an agalactosyl fucosylated biantennary oligosaccharide form (sum NGA2F+NGA2F-GlcNAc).<p>[DC]</p> 8. The composition of claim 1, wherein said adalimumab has been produced by culturing a mammalian cell in a cell culture media which has been supplemented with a manganese supplement and a galactose supplement.<p>[DC]</p> 9. The composition of claim 1, wherein said adalimumab has been produced by culturing a mammalian cell in a cell culture media comprising 0.2-100 M of a manganese supplement and 1-100 mM of a galactose supplement.<p>[DC]</p> 10. The composition of claim 9, wherein the cell culture media comprises a hydrolysate based media or a chemically defined media.<p>[DC]</p> 11. The composition of claim 9, wherein the mammalian cell is a CHO cell.<p>[DC]</p> 12. The pharmaceutical composition of claim 11 and a pharmaceutically acceptable carrier comprising a polyalcohol.<p>[DC]</p> 13. The pharmaceutical composition of claim 12, wherein the pharmaceutically acceptable carrier further comprises polysorbate 80.<p>[DC]</p>  14. The pharmaceutical composition of claim 13, wherein the pharmaceutical composition is suitable for subcutaneous administration and is formulated in a pre-filled syringe.<p>[DC]</p> 15. A pharmaceutical composition comprising the composition of claim 1 and a pharmaceutically acceptable carrier.<p>[DC]</p> 16. The pharmaceutical composition of claim 15, wherein the pharmaceutically acceptable carrier comprises mannitol.<p>[DC]</p> 17. The pharmaceutical composition of claim 15, wherein the pharmaceutically acceptable carrier comprises sodium chloride.<p>[DC]</p> 18. The pharmaceutical composition of claim 15, wherein the pharmaceutically acceptable carrier comprises polysorbate 80.<p>[DC]</p> 19. The pharmaceutical composition of claim 15, wherein the pharmaceutically acceptable carrier comprises sodium phosphate.<p>[DC]</p> 20. The pharmaceutical composition of claim 15, wherein the pharmaceutical composition is suitable for parenteral administration.<p>[DC]</p> 21. The pharmaceutical composition of claim 15, wherein the pharmaceutical composition is suitable for subcutaneous administration and is formulated in a pre-filled syringe.",
               "source":"<p>Source:</p> US9255143B2, Abott Biotech Company: Humira® Product"
            },
            {  
               "name":"Crystal",
               "color":"green",
               "claimReason":"“ ... A crystal of an IgG human anti-hTNFalpha antibody comprising two heavy chains each with a molecular weight of about 50 kDa and comprising a light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO: 1 …”",
               "indClaim":"<p>[IC]</p> 1. A crystal of an IgG human anti-hTNFalpha antibody comprising two heavy chains each with a molecular weight of about 50 kDa and comprising a light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO: 1, and a heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO: 2, wherein said crystal has a needle morphology with a length of about 2-500 m and an l/d ratio of about 3 to 30.",
               "depClaim":"<p>[DC]</p> 2. The crystal according to claim 1, wherein said antibody is selected from the group consisting of: IgG1, IgG2, IgG3 and IgG4 antibodies.<p>[DC]</p> 3. The crystal according to claim 1, wherein said antibody is an IgG1 antibody.<p>[DC]</p> 4. The crystal according to claim 1, wherein the antibody is adalimumab (D2E7).<p>[DC]</p> 5. A pharmaceutical composition comprising: <p>(a)</p> crystals of an anti-hTNFalpha antibody according to claim 1, and <p>(b)</p> at least one pharmaceutical excipient; wherein the composition is provided as a solid, semisolid or liquid formulation, each formulation containing said antibody in crystalline form.<p>[DC]</p> 6. A pharmaceutical composition comprising: <p>(a)</p> crystals of an anti-hTNFalpha antibody according to claim 1, and <p>(b)</p> at least one pharmaceutical excipient, which embeds or encapsulates crystals of said antibody.<p>[DC]</p> 7. The composition according to claim 5, wherein said composition has an antibody concentration greater than about 1 mg/ml.<p>[DC]</p> 8. The composition according to claim 5, wherein said composition has an antibody concentration greater than about 200 mg/ml.<p>[DC]</p> 9. The composition according to claim 5, wherein said excipient comprises at least one polymeric optionally biodegradable carrier or at least one oil or lipid carrier.<p>[DC]</p> 10. The composition according to claim 9, wherein said polymeric carrier is a polymer selected from one or more of the group consisting of: poly (acrylic acid), poly (cyanoacrylates), poly (amino acids), poly (anhydrides), poly (depsipeptide), poly (esters), poly (lactic acid), poly (lactic-coglycolic acid) or PLGA, poly (-hydroxybutryate), poly (caprolactone), poly (dioxanone); poly (ethylene glycol), poly (hydroxypropyl) methacrylamide, poly (organo) phosphazene, poly (ortho esters), poly (vinyl alcohol), poly (vinylpyrrolidone), maleic anhydride alkyl vinyl ether copolymers, pluronic polyols, albumin, alginate, cellulose and cellulose derivatives, collagen, fibrin, gelatin, hyaluronic acid, oligosaccharides, glycaminoglycans, sulfated polysaccharides, blends and copolymers thereof.<p>[DC]</p> 11. An injectable liquid composition comprising anti-hTNFalpha antibody crystals according to claim 1 and having an antibody concentration in the range of about 10 to 400 mg/ml.<p>[DC]</p> 12. A crystal slurry comprising anti-hTNFalpha antibody crystals according to claim 1, having an antibody concentration greater than about 100 mg/ml.",
               "source":"<p>Source:</p> US8436149B2, Abott Biotech Company: Humira® Product"
            },
            {  
               "name":"Chimeric",
               "color":"green",
               "claimReason":"“… chimeric antibody comprising at least part of a human immunoglobulin constant region and at least part of a non-human immunoglobulin variable region …”",
               "indClaim":"<p>[IC]</p> 1. A chimeric antibody comprising at least part of a human immunoglobulin constant region and at least part of a non-human immunoglobulin variable region, said antibody capable of binding an epitope specific for human tumor necrosis factor TNF, wherein the non-human immunoglobulin variable region comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 3 and SEQ ID NO: 5.",
               "depClaim":"<p>[DC]</p> 2. An immunoassay method for detecting human TNF in a sample, comprising: <p>(a)</p> contacting said sample with an antibody according to claim 1, or a TNF binding fragment thereof, in detectably labeled form; and <p>(b)</p> detecting the binding of the antibody to said TNF.",
               "source":"<p>Source:</p> US6284471B1, Janssen Bio. Company: Remicade® Product"
            }
         ]
      },
      {  
         "name":"Polynucleotide",
         "color":"yellow",
         "children":[  
            {  
               "name":"Vector",
               "color":"yellow",
               "claimReason":"“… recombinant expression vector element (rEVE) polynucleotide molecule comprising a nucleotide base sequence selected from the group consisting of the nucleotide base sequence of SEQ ID NO:1 …”",
               "indClaim":"<p>[IC]</p> 1. An isolated recombinant expression vector element (rEVE) polynucleotide molecule comprising a nucleotide base sequence selected from the group consisting of the nucleotide base sequence of SEQ ID NO:1, the nucleotide base sequence of SEQ ID NO:2, a sequence complementary to any foregoing sequence, an expression-enhancing portion of any foregoing sequence, and combinations thereof.",
               "depClaim":"<p>[DC]</p> 2. The isolated rEVE polynucleotide molecule according to claim 1, wherein the rEVE polynucleotide molecule comprises an expression-enhancing portion of the sequence of SEQ ID NO:2 selected from the group consisting of the sequence of bases 462-2422 of SEQ ID NO:2 and the sequence of bases 1087-2422 of SEQ ID NO:2.<p>[DC]</p> 3. A recombinant vector comprising a rEVE polynucleotide molecule as described in claim 1.<p>[DC]</p> 4. The recombinant vector according to claim 3, wherein the recombinant vector is a recombinant expression vector.<p>[DC]</p> 5. The recombinant expression vector according to claim 4 selected from the group consisting of a recombinant plasmid expression vector, a recombinant eukaryotic viral expression vector, a recombinant bacteriophage expression vector, a recombinant yeast mini-chromosome expression vector, a recombinant bacterial artificial chromosome expression vector, and a recombinant yeast expression plasmid vector.<p>[DC]</p> 6. The recombinant expression vector according to claim 4, wherein the recombinant expression vector comprises one or more functional recombinant genes encoding one or more recombinant proteins.<p>[DC]</p> 7. The recombinant expression vector according to claim 6, wherein said one or more recombinant proteins is selected from the group consisting of a soluble protein, a membrane protein, a structural protein, a ribosomal protein, an enzyme, a zymogen, an antibody molecule, a cell surface receptor protein, a transcription regulatory protein, a translation regulatory protein, a chromatin protein, a hormone, a cell cycle regulatory protein, a G protein, a neuroactive peptide, an immunoregulatory protein, a blood component protein, an ion gate protein, a heat shock protein, a dihydrofolate reductase (DHFR), an antibiotic resistance protein, a functional fragment of any of the preceding proteins, an epitope-containing fragment of any of the preceding proteins, and combinations thereof.<p>[DC]</p> 8. The recombinant expression vector according to claim 7, wherein the antibody molecule is selected from the group consisting of an anti-TNF- antibody, an anti-EL-selectin antibody, an anti-IL-13 antibody, and a dual variable domain immunoglobulin molecule.<p>[DC]</p> 9. The recombinant expression vector according to claim 8, wherein the anti-TNF- antibody is adalimumab.<p>[DC]</p> 10. The recombinant expression vector according to any one of claims 4-9, wherein said recombinant expression vector comprises at least one copy of a gene encoding a dihydrofolate reductase.<p>[DC]</p> 11. A host cell comprising a vector described in any one of claims 3-9.<p>[DC]</p> 12. The host cell according to claim 11, wherein the host cell is a eukaryotic host cell or a prokaryotic host cell.<p>[DC]</p> 13. The host cell according to claim 12, wherein the host cell is a eukaryotic host cell selected from the group consisting of a mammalian host cell, an insect host cell, a plant host cell, a fungal host cell, a eukaryotic algal host cell, a nematode host cell, a protozoan host cell, and a fish host cell.<p>[DC]</p> 14. The host cell according to claim 13, wherein the eukaryotic host cell is a mammalian host cell.<p>[DC]</p> 15. The host cell according to claim 14, wherein the mammalian host cell is selected from the group consisting of a Chinese Hamster Ovary (CHO) cell, a COS cell, a Vero cell, an SP2/0 cell, an NS/0 myeloma cell, a human embryonic kidney (HEK 293) cell, a baby hamster kidney (BHK) cell, a HeLa cell, a human B cell, a CV-1/EBNA cell, an L cell, a 3T3 cell, an HEPG2 cell, a PerC6 cell, and an MDCK cell.<p>[DC]</p> 16. The host cell according to claim 15, wherein the mammalian host cell is a CHO cell.<p>[DC]</p> 17. The host cell according to claim 13, wherein the eukaryotic host cell is a fungal host cell.<p>[DC]</p> 18. The host cell according to claim 17, wherein the fungal host cell is selected from the group consisting of Aspergillus, Neurospora, Saccharomyces, Pichia, Hansenula, Schizosaccharomyces, Kluyveromyces, Yarrowia, and Candida.<p>[DC]</p> 19. The host cell according to claim 18, wherein the Saccaromyces host cell is an S. cerevisiae host cell.<p>[DC]</p> 20. The host cell according to claim 13, wherein the eukaryotic host cell is a protozoan host cell.<p>[DC]</p> 21. The host cell according to claim 20, wherein the protozoan host cell is a Leishmania tarentolae host cell.<p>[DC]</p> 22. A method of producing a recombinant protein of interest comprising transcribing and translating one or more genes encoding the recombinant protein of interest present on a recombinant expression vector described in any of claims 4-9.<p>[DC]</p> 23. The method according to claim 22, wherein said transcribing and translating occur in a cellfree transcription/translation system or in a host cell.<p>[DC]</p> 24. The method according to claim 23, wherein said transcribing and translating occur in a host cell.<p>[DC]</p> 25. The method according claim 24, wherein said host cell is a CHO host cell.<p>[DC]</p> 26. A method of producing a host cell that stably expresses elevated levels of a recombinant protein of interest, comprising: <p>(a)</p>inserting into host cells a recombinant expression vector described in claim 10, growing said host cells in the presence of methotrexate to select for a methotrexate-resistant host cell that expresses the recombinant protein of interest, and isolating said methotrexate-resistant host cell, wherein said isolated methotrexate-resistant host cell expresses the recombinant protein of interest at a level that is higher than that of a methotrexate-sensitive host cell, and wherein said methotrexate-resistant host cell stably expresses an elevated level of the recombinant protein when grown in the presence or in the absence of methotrexate.<p>[DC]</p> 27. The method according to claim 26, wherein said methotrexate is present at a concentration in the range of 5 nM to 10 M.<p>[DC]</p> 28. The method according to claim 26, wherein said host cell is a CHO host cell.<p>[DC]</p> 29. In a dihydrofolate reductase (DHFR)-methotrexate method for amplifying the expression of a recombinant protein of interest encoded on a recombinant expression vector in a host cell, wherein said recombinant expression vector comprises a gene coding for the recombinant protein of interest and a gene encoding DHFR, the improvement wherein said recombinant expression vector also comprises a rEVE polynucleotide molecule as described in claim 1 or claim 2, wherein growth of host cells containing the expression vector in the presence of methotrexate selects for and produces a methotrexate-resistant host cell that stably expresses the recombinant protein of interest at an amplified level when grown in the presence or in the absence of methotrexate.<p>[DC]</p> 30. The method according to claim 29, wherein said methotrexate is present at a concentration in the range of 5 nM to 10 M.<p>[DC]</p> 31. The method according to claim 29, wherein said host cell is a CHO host cell.",
               "source":"<p>Source:</p> US7935808B2, Abott Biotech Company: Humira® Product"
            },
            {  
               "name":"Sequence",
               "color":"yellow",
               "claimReason":"“… comprising a first polynucleotide and a second polynucleotide, wherein the first polynucleotide encodes a heavy chain comprising …”",
               "indClaim":"<p>[IC]</p> 1. A composition comprising a first polynucleotide and a second polynucleotide, wherein the first polynucleotide encodes a heavy chain comprising CDR1, CDR2, and CDR3 of SEQ ID NO: 13 and the second polynucleotide encodes a light chain comprising CDR1, CDR2, and CDR3 of SEQ ID NO: 14, wherein an antibody comprising the heavy chain and the light chain interacts with a human osteoprotegerin ligand (OPGL) and inhibits binding of human OPGL to an osteoclast differentiation and activation receptor (ODAR).",
               "depClaim":"<p>[DC]</p> 2. The composition of claim 1, wherein the first polynucleotide and the second polynucleotide are part of the same nucleic acid molecule.<p>[DC]</p> 3. The composition of claim 1, wherein the first polynucleotide and the second polynucleotide are operably linked such that they encode a single-chain antibody.<p>[DC]</p> 4. The composition of claim 3, wherein the single-chain antibody is a single-chain Fv antibody.<p>[DC]</p> 5. The composition of claim 1, which encodes a Fab antibody.<p>[DC]</p> 6. The composition of claim 1, which encodes a Fab antibody.<p>[DC]</p> 7. The composition of claim 1, which encodes a F(ab)2 antibody.<p>[DC]</p> 8. The composition of claim 1, which encodes a fully human antibody.",
               "source":"<p>Source:</p> US8058418B2, Amgen Company: Xgeva® Product"
            }
         ]
      },
      {  
         "name":"Formulation & Composition",
         "color":"blue",
         "children":[  
            {  
               "name":"Macro",
               "color":"blue",
               "children":[  
                  {  
                     "name":"Dosage Form",
                     "color":"blue",
                     "claimReason":"“… a form selected from the group consisting of a liquid, a semi-solid dosage form, a solid dosage form, a dispersion, a suspension, a tablet, a pill, a powder, a liposome, and a suppositor …”",
                     "indClaim":"<p>[IC]</p> 54. A pharmaceutical composition comprising an isolated human antibody, or antigen-binding portion thereof, which dissociates from human TNF with a Kd of 1×108 M or less and a Koff rate constant of 1×103 s1 or less, both determined by surface plasmon resonance, and neutralizes human TNF cytotoxicity in a standard in vitro L929 assay with an IC50 of 1×107 M or less, and a pharmaceutically acceptable carrier, wherein the composition has a form selected from the group consisting of a liquid, a semi-solid dosage form, a solid dosage form, a dispersion, a suspension, a tablet, a pill, a powder, a liposome, and a suppository.",
                     "depClaim":"<p>[DC]</p> None.",
                     "source":"<p>Source:</p> US8414894B2, Abott Biotech Company: Humira® Product"
                  },
                  {  
                     "name":"Pharmaceutical Carrier",
                     "color":"blue",
                     "claimReason":"“… wherein the pharmaceutically acceptable carrier is selected from the group consisting of water, saline, phosphate buffered saline, dextrose, glycerol, ethanol, an isotonic agent, a sugar, a polyalcohol, mannitol, sorbitol, and sodium chloride …”",
                     "indClaim":"<p>[IC]</p> 84. A pharmaceutical composition comprising an isolated human anti-TNF antibody, or antigenbinding portion thereof, and a pharmaceutically acceptable carrier, wherein the pharmaceutically acceptable carrier is selected from the group consisting of water, saline, phosphate buffered saline, dextrose, glycerol, ethanol, an isotonic agent, a sugar, a polyalcohol, mannitol, sorbitol, and sodium chloride, and wherein the antibody or antigen-binding portion thereof, comprises an IgG1 heavy chain, comprises a light chain variable region (LCVR) comprising a CDR3 domain comprising the amino acid sequence of SEQ ID NO: 3, or modified from SEQ ID NO: 3 by a single alanine substitution at position 1, 4, 5, 7 or 8 or by one to five conservative amino acid substitutions at positions 1, 3, 4, 6, 7, 8 and/or 9, a CDR2 domain comprising the amino acid sequence of SEQ ID NO: 5, and a CDR1 domain comprising the amino acid sequence of SEQ ID NO: 7; and comprises a heavy chain variable region (HCVR) having a CDR3 domain comprising the amino acid sequence of SEQ ID NO: 4, or modified from SEQ ID NO: 4 by a single alanine substitution at position 2, 3, 4, 5, 6, 8, 9, 10 or 11 or by one to five conservative amino acid substitutions at positions 2, 3, 4, 5, 6, 8, 9, 10, 11 and/or 12, a CDR2 domain comprising the amino acid sequence of SEQ ID NO: 6, and a CDR1 domain comprising the amino acid sequence of SEQ ID NO: 8.",
                     "depClaim":"<p>[DC]</p> None.",
                     "source":"<p>Source:</p> US8414894B2, Abott Biotech Company: Humira® Product"
                  }
               ]
            },
            {  
               "name":"Micro (Concentration, PH, Mass, Conducitivity etc)",
               "color":"blue",
               "children":[  
                  {  
                     "name":"Components",
                     "color":"blue"
                  },
                  {  
                     "name":"Hydrodynamic diameter",
                     "color":"blue",
                     "claimReason":"“… has a hydrodynamic diameter (Dh) of less than about 4 nm …”",
                     "indClaim":"<p>[IC]</p> 28. An aqueous formulation comprising an antibody, or an antigen-binding fragment, at a concentration of at least about 20 mg/mL, and water, wherein the antibody, or antigen-binding fragment, has a hydrodynamic diameter (Dh) of less than about 4 nm, and wherein the antibody, or antigen-binding fragment thereof, has a molecular weight (Mw) greater than about 47 kDa.",
                     "depClaim":"<p>[DC]</p> 29. The formulation of claim 28, wherein the antibody has a Dh of less than about 3 nm.<p>[DC]</p> 30. The formulation of claim 28, wherein the antibody, or antigen-binding fragment thereof, is selected from the group consisting of a chimeric antibody, a human antibody, a humanized antibody, and a domain antibody (dAb).<p>[DC]</p> 31. The formulation of claim 28, wherein the antibody, or antigen-binding fragment thereof, is an anti-TNF-alpha or an anti-IL-12 antibody, or antigen-binding fragment thereof.<p>[DC]</p> 32. The formulation of claim 28, wherein the antibody, or antigen-binding fragment thereof, is selected from the group consisting of, alemtuzumab, arcitumomab, cetuximab, trastuzumab, imciromab pentetate, capromab pendetide, infliximab, abciximab, rituximab, basiliximab, palivizumab, nofetumomab, omalizumab, daclizumab, ibritumomab tiuxetan, muromonab-CD3, edrecolomab gemtuzumab ozogamicin, golimumab, certolizumab pegol, eculizumab, ustekinumab, panitumumab, tositumomab, I131 tositumomab, and bevacizumab.<p>[DC]</p> 33. The formulation of claim 28, wherein the antibody, or antigen-binding fragment thereof, is adalimumab.<p>[DC]</p> 34. The formulation of any one of claims 1, 13, 17, and 28, further comprising a non-ionizable excipient.<p>[DC]</p> 35. The formulation of claim 34, wherein the non-ionizable excipient is selected from the group consisting of a polyol, a non-ionic surfactant, sucrose, trehalose, raffinose, and maltose.<p>[DC]</p> 36. The formulation of claim 35, wherein the polyol is mannitol or sorbitol.<p>[DC]</p> 37. The formulation of claim 35, wherein the non-ionic surfactant is polysorbate 20, polysorbate 40, polysorbate 60 or polysorbate 80.<p>[DC]</p> 38. The formulation of any one of claims 1, 13, 17, and 28, wherein the formulation is stable in a liquid form for at least about 3 months or at least about 12 months.<p>[DC]</p> 39. The formulation of any one of claims 1, 13, 17, and 28, wherein the formulation does not comprise an agent selected from the group consisting of a tonicity modifier, a stabilizing agent, a surfactant, an anti-oxidant, a cryoprotectant, a bulking agent, a lyroprotectant, a basic component, and an acidic component.<p>[DC]</p> 40. The formulation of any one of claims 1, 13, 17, and 28, wherein the formulation is suitable for in vitro or in vivo use.<p>[DC]</p> 41. The formulation of claim 40, wherein the formulation is suitable for administration to a subject via a mode of administration selected from the group consisting of subcutaneous, intravenous, inhalation, intradermal, transdermal, intraperitoneal, and intramuscular.",
                     "source":"<p>Source:</p> US8420081B2, Abott Biotech Company: Humira® Product"
                  },
                  {  
                     "name":"PH Value",
                     "color":"blue",
                     "claimReason":"“… formulation comprising an antibody that binds to VEGF in an arginine acetate buffer at a pH from about 4.5 to about 6.0 …”",
                     "indClaim":"<p>[IC]</p> 24. A pharmaceutical formulation comprising an antibody that binds to VEGF in an arginine acetate buffer at a pH from about 4.5 to about 6.0, and a surfactant, wherein the antibody is bevacizumab.",
                     "depClaim":"<p>[DC]</p> 25. The pharmaceutical formulation of claim 24, wherein the arginine acetate buffer is pH 4.5 to 5.5.<p>[DC]</p> 26. The pharmaceutical formulation of claim 24, wherein the arginine acetate buffer is pH 4.8 to 5.4.<p>[DC]</p> 27. The pharmaceutical formulation of claim 24, wherein the arginine acetate buffer is pH 5.2.<p>[DC]</p> 28. The pharmaceutical formulation of claim 25, wherein the arginine actetate concentration in the buffer is from about 25 mm to about 250 mm.<p>[DC]</p> 29. The pharmaceutical formulation of claim 25, wherein the arginine actetate concentration in the buffer is from about 50 mm to about 250 mm.<p>[DC]</p> 30. The pharmaceutical formulation of claim 25, wherein the arginine actetate concentration in the buffer is from about 75 mm to about 250 mm.<p>[DC]</p> 31. The pharmaceutical formulation of claim 25, wherein the arginine actetate concentration in the buffer is from about 100 mm to about 250 mm.<p>[DC]</p> 32. The pharmaceutical formulation of claim 25, wherein the arginine acetate concentration in the buffer is from about 120 mm to about 240 mm.<p>[DC]</p> 33. The pharmaceutical formulation of claim 25, wherein arginine acetate concentration in the buffer is from about 150 mm to about 225 mm.<p>[DC]</p> 34. The pharmaceutical formulation of claim 25, wherein the arginine acetate concentration in the buffer is about 200 mm.<p>[DC]</p> 35. The pharmaceutical formulation of claim 24, wherein the surfactant is polysorbate.<p>[DC]</p> 36. The pharmaceutical formulation of claim 35, wherein the polysorbate is polysorbate 20.<p>[DC]</p> 37. The pharmaceutical formulation of claim 24, wherein the surfactant concentration is from about 0.0001% to about 1.0%.<p>[DC]</p> 38. The pharmaceutical formulation of claim 24, wherein the surfactant concentration is from about 0.01% to about 0.05%.<p>[DC]</p> 39. The pharmaceutical formulation of claim 24, wherein the surfactant concentration is 0.04%.<p>[DC]</p> 40. The pharmaceutical formulation of claim 24, wherein the antibody concentration is from about 10 mg/ml to about 250 mg/ml.<p>[DC]</p> 41. The pharmaceutical formulation of claim 24, wherein the antibody concentration is from about 25 mg/ml to about 200 mg/ml.<p>[DC]</p> 42. The pharmaceutical formulation of claim 24, wherein the antibody concentration is from about 50 mg/ml to about 150 mg/ml.<p>[DC]</p> 43. The pharmaceutical formulation of claim 24, wherein the antibody concentration is from about 75 mg/ml to about 125 mg/ml.<p>[DC]</p> 44. The pharmaceutical formulation of claim 36, wherein the antibody concentration is about 75 mg/ml to about 125 mg/ml, the arginine acetate buffer is pH 4.8 to 5.4, the arginine acetate concentration in the buffer is from about 150 mM to about 225 mM, and the polysorbate 20 concentration is from about 0.01% to about 0.05%.<p>[DC]</p> 45. The pharmaceutical formulation of claim 44, wherein the antibody concentration is about 100 mg/ml, the arginine acetate buffer is pH 5.2, the arginine acetate concentration in the buffer is about 200 mM, and the polysorbate 20 concentration is 0.04%.<p>[DC]</p> 46. The pharmaceutical formulation of claim 24, wherein the antibody is not subject to prior lyophilization.<p>[DC]</p> 47. The pharmaceutical formulation of claim 24 which is sterile.<p>[DC]</p> 48. The pharmaceutical formulation of claim 24 which is stable upon storage at about 40° C. for at least 28 days.<p>[DC]</p> 49. The pharmaceutical formulation of claim 24 which is aqueous and is administered to a subject.<p>[DC]</p> 50. The pharmaceutical formulation of claim 49, wherein the pharmaceutical formulation is for intravenous (IV), subcutaneous (SQ) or intramuscular (IM) administration.<p>[DC]</p> 51. The pharmaceutical formulation of claim 49, which is for IV administration and the antibody concentration is from about 10 mg/ml to about 250 mg/ml.<p>[DC]</p> 52. The pharmaceutical formulation of claim 49, which is for IV administration and the antibody concentration is from about 50 mg/ml to about 100 mg/ml.<p>[DC]</p> 53. The pharmaceutical formulation of claim 49, which is for SQ administration and the antibody concentration is from about 25 mg/ml to about 250 mg/ml.<p>[DC]</p> 54. The pharmaceutical formulation of claim 49, which is for SQ administration and the antibody concentration is from about 50 mg/ml to about 100 mg/ml.<p>[DC]</p> 55. A vial with a stopper pierceable by a syringe comprising the pharmaceutical formulation of claim 24 inside the vial.<p>[DC]</p> 56. The vial of claim 55 which is stored at about 2-8° C.<p>[DC]</p> 57. The vial of claim 55 which is a 3 cc, 20 cc or 50 cc vial.<p>[DC]</p> 58. The vial of claim 55, wherein the antibody concentration in the formulation is about 75 mg/ml to about 125 mg/ml, the arginine acetate buffer is pH 4.8 to 5.4, the arginine acetate concentration in the buffer is from about 150 mM to about 225 mM, and the surfactant is polysorbate 20 at a concentration from about 0.01% to about 0.05%.<p>[DC]</p> 59. The vial of claim 58, wherein the antibody concentration in the formulation is about 100 mg/ml, the arginine acetate buffer is pH 5.2, the arginine acetate concentration in the buffer is about 200 mM, and the polysorbate 20 concentration is 0.04%.<p>[DC]</p> 60. A stainless steel tank comprising the pharmaceutical formulation of claim 24 inside the tank.<p>[DC]</p> 61. The tank of claim 56 wherein the pharmaceutical formulation is frozen.<p>[DC]</p> 62. The tank of claim 60, wherein the antibody concentration in the formulation is about 75 mg/ml to about 125 mg/ml, the arginine acetate buffer is pH 4.8 to 5.4, the arginine acetate concentration in the buffer is from about 150 mM to about 225 mM, and the surfactant is polysorbate 20 at a concentration from about 0.01% to about 0.05%.<p>[DC]</p> 63. The tank of claim 62, wherein the antibody concentration in the formulation is about 100 mg/ml, the arginine acetate buffer is pH 5.2, the arginine acetate concentration in the buffer is about 200 mM, and the polysorbate 20 concentration is 0.04%.",
                     "source":"<p>Source:</p> US9226961B2, Genentech Company: Avastin® Product"
                  },
                  {  
                     "name":"Aggregation",
                     "color":"blue",
                     "claimReason":"“… <3% aggregates when formulated at a concentration of about 150 mg/mL …”",
                     "indClaim":"<p>[IC]</p> 1. A method of treating a patient suffering from multiple sclerosis, comprising administering to the patient an amount of a daclizumab composition sufficient to provide therapeutic benefit, wherein the daclizumab has two or more of the following: <p>(a)</p> an N-terminal isoform with one pyroglutamate residue and one glutamine residue that comprises 3%-17% of the total daclizumab: <p>(b)</p> an N-linked oligosaccharide profile comprising two main peaks and a minor peak, wherein one of the two main peaks is GO-GlcNAc glycoform present in about 5% to about 20% of the AUC, the other main peak is GO glycoform present in about 70% to about 99.2% of the AUC, and the minor peak is G1 glycoform present in 1% to 9% of the AUC when determined according to the method described in Section 7.6.14, <p>(c)</p> <3% aggregates when formulated at a concentration of about 150 mg/mL.",
                     "depClaim":"<p>[DC]</p> 2. The method of claim 1 in which the daclizumab composition is administered: <p>(a)</p> subcutaneously; <p>(b)</p> in an amount corresponding to about 1 mg/kg daclizumab, once every two weeks or in an amount corresponding to about 2 mg/kg daclizumab, once every month; <p>(c)</p> for a total of about 24 weeks; or <p>(d)</p> according to any combination of (a)-(c).<p>[DC]</p> 3. The method of claim 2, in which the daclizumab composition is administered in an amount corresponding to 75 mg to 300 mg daclizumab, or 150 mg, or 300 mg.<p>[DC]</p> 4. The method of claim 3 wherein the daclizumab composition is administered subcutaneously in an amount corresponding to 150 mg daclizumab once every month.<p>[DC]</p> 5. The method of claim 3 in which the daclizumab is administered as monotherapy, in which the patient has either failed to respond to prior treatment with interferon-beta or has discontinued prior treatment with interferon-beta.<p>[DC]</p> 7. The method of claim 1 in which the daclizumab has an N-linked glycosylation profile determined according to the method described in Section 7.6.14, in which the total AUC of the peaks in the profile corresponding to non-fucosylated mannose glycosyls is less than about 6% of the total AUC of all peaks in the profile.<p>[DC]</p> 8. The method of claim 4 which is administered for a total of at least 48 weeks.",
                     "source":"<p>Source:</p> US9676860B2, Biogen Company: Zinbryta® Product"
                  },
                  {  
                     "name":"Multiple Antibodies",
                     "color":"blue",
                     "claimReason":"“… acidic variants of the main species antibody, wherein the acidic variants include …”",
                     "indClaim":"<p>[IC]</p> 1. A method of treating HER2 positive cancer in a patient comprising administering a pharmaceutical formulation to the patient in an amount effective to treat the cancer, wherein the pharmaceutical formulation comprises a composition comprising a main species HER2 antibody comprising variable light and variable heavy sequences comprising SEQ ID Nos. 3 and 4, respectively, and acidic variants of the main species antibody, wherein the acidic variants include a glycated variant, a deamidated variant, a disulfide reduced variant, a sialylated variant, and a non-reducible variant in a pharmaceutically acceptable carrier.",
                     "depClaim":"<p>[DC]</p> 2. The method of claim 1 wherein the cancer is breast cancer.<p>[DC]</p> 3. The method of claim 1 wherein the main species antibody and acidic variants have essentially the same pharmacokinetics.<p>[DC]</p> 4. The method of claim 1 wherein the composition comprises less than about 25% acidic variants.<p>[DC]</p> 5. The method of claim 1 wherein the main species HER2 antibody and the acidic variants are intact antibodies.<p>[DC]</p> 6. The method of claim 1 wherein the main species HER2 antibody comprises light chain and heavy chain amino acid sequences comprising SEQ ID Nos. 15 and 16, respectively.<p>[DC]</p> 7. The method of claim 1 wherein the composition further comprises an amino-terminal leader extension variant of the main species antibody.<p>[DC]</p> 8. The method of claim 7 wherein the amino-terminal leader extension comprises VHS-.<p>[DC]</p> 9. The method of claim 7 wherein the amino-terminal leader extension consists of VHS-.<p>[DC]</p> 10. The method of claim 1 wherein the composition further comprises an amino acid sequence variant of the main species HER2 antibody selected from the group consisting of an antibody comprising a C-terminal lysine residue on one or both heavy chains thereof, and an antibody with one or more oxidized methionine residues.",
                     "source":"<p>Source:</p> US9181346B2, Genentech Company: Perjeta® Product"
                  }
               ]
            }
         ]
      },
      {  
         "name":"Treatment",
         "children":[  
            {  
               "name":"Treatment for Condition XYZ",
               "color":"red",
               "children":[  
                  {  
                     "name":"In Vivo",
                     "color":"red",
                     "claimReason":"“… method for treating a subject suffering from rheumatoid arthritis, comprising administering to the subject …”",
                     "indClaim":"<p>[IC]</p> 9. A method for treating a subject suffering from rheumatoid arthritis, comprising administering to the subject both an antibody and methotrexate, such that the rheumatoid arthritis is treated, wherein the antibody is an isolated human antibody, or antigen-binding portion thereof, with the following characteristics: <p>a)</p> dissociates from human INF with a K off rate constant 1×10-3 s-1 or less, as determined by surface plasmon resonance; <p>b)</p> has a light chain CDR3 domain comprising the amino acid sequence of SEQ ID NO: 3, or modified from SEQ ID NO: 3 by a single alanine substitution at position 1,4, 5, 7 or 8 or by one to five conservative amino avid substitutions at positions 1, 3, 4, 6, 7, 8 and/or 9; <p>c)</p> has a heavy chain CDR3 domain comprising the amino acid sequence of SEQ ID NO: 4, or modified from SEQ ID NO: 4 by a single alanine substitution at position 2, 3, 4, 5, 6, 8, 9, 10 or 11 or by one to five conservative amino acid substitutions at positions 2, 3, 4, 5, 6, 8, 9, 10, 11 and/or 12.",
                     "depClaim":"<p>[DC]</p> None.",
                     "source":"<p>Source:</p> US7223394B2, Abott Biotech Company: Humira® Product"
                  },
                  {  
                     "name":"In Vitro",
                     "color":"red",
                     "claimReason":"“… method of treating a subject having a CD38-positive hematological malignancy … wherein the anti-CD38 antibody induces in vitro killing of CD38-expressing cells …”",
                     "indClaim":"<p>[IC]</p> 1. A method of treating a subject having a CD38-positive hematological malignancy, comprising administering to the subject in need thereof an anti-CD38 antibody in combination with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP), wherein the anti-CD38 antibody induces in vitro killing of CD38-expressing cells by antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), complement dependent cytotoxicity (CDC), apoptosis, or in vitro modulation of CD38 enzymatic activity and comprises heavy chain complementarity determining region (HCDR) 1 (HCDR1), 2 (HCDR2) and 3 (HCDR3) sequences of SEQ ID NOs: 6, 7 and 8, respectively, and light chain complementarity determining region (LCDR) 1 (LCDR1), 2 (LCDR2) and 3 (LCDR3) sequences of SEQ ID NOs: 9, 10 and 11, respectively, wherein the subject is resistant to or has acquired resistance to treatment with at least one chemotherapeutic agent.",
                     "depClaim":"<p>[DC]</p> 2. The method of claim 1, wherein the anti-CD38 antibody induces killing of the CD38-expressing cells by ADCC or CDC in vitro.<p>[DC]</p> 3. The method of claim 2, wherein the anti-CD38 antibody is of IgG1, IgG2, IgG3 or IgG4 isotype.<p>[DC]</p> 4. The method of claim 3, wherein the anti-CD38 antibody has a biantennary glycan structure with fucose content of about 50%, 45%, 40%, 35%, 30%, 25%, 20%, 15%, 14%, 13%, 12%, 11% 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1% or 0%.<p>[DC]</p> 5. The method of claim 3, wherein the anti-CD38 antibody comprises a substitution in the antibody Fc at amino acid position 256, 290, 298, 312, 356, 330, 333, 334, 360, 378 or 430, wherein residue numbering is according to the EU index.<p>[DC]</p> 6. The method of claim 1, wherein the anti-CD38 antibody comprises a heavy chain variable region (VH) of SEQ ID NO: 4 and a light chain variable region (VL) of SEQ ID NO: 5.<p>[DC]</p> 7. The method of claim 6, wherein the anti-CD38 antibody comprises a heavy chain of SEQ ID NO: 12 and a light chain of SEQ ID NO: 13.<p>[DC]</p> 8. The method of claim 1, wherein the CD38-positive hematological malignancy is multiple myeloma, acute lymphoblastic leukemia (ALL), non-Hodgkin's lymphoma (NHL), diffuse large Bcell lymphoma (DLBCL), Burkitt's lymphoma (BL), follicular lymphoma (FL) or mantle-cell lymphoma (MCL).<p>[DC]</p> 9. The method of claim 8, wherein the CD38-positive hematological malignancy is DLBCL.<p>[DC]</p> 10. The method of claim 8, wherein the subject is resistant to or has acquired resistance to treatment with a combination of at least one chemotherapeutic agent and an anti-CD20 antibody.<p>[DC]</p> 11. The method of claim 8, wherein the subject has discontinued treatment with at least one chemotherapeutic agent or a combination of at least one chemotherapeutic agent and an anti- CD20 antibody due to side effects.<p>[DC]</p> 12. The method of claim 10 or 11, wherein the anti-CD20 antibody is rituximab (RITUXAN®), ofatumumab (ARZERRA®), veltuzumab, ocrelizumab, obinutuzumab (GA-101), PRO13192 or ocratuzumab (AME-133v).<p>[DC]</p> 13. The method of claim 12, wherein the anti-CD20 antibody is rituximab.<p>[DC]</p> 14. The method of claim 10 or 11, wherein the at least one chemotherapeutic agent is cyclophosphamide, doxorubicin, vincristine, prednisone, ifosfamide, carboplatin or etoposide.<p>[DC]</p> 15. The method of claim 14, wherein the at least one chemotherapeutic agent is a combination of cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP).<p>[DC]</p> 16. The method of claim 14, wherein the at least one chemotherapeutic agent is a combination of ifosfamide, carboplatin and etoposide (ICE).<p>[DC]</p> 17. The method of claim 1, wherein the anti-CD38 antibody, cyclophosphamide, doxorubicin, vincristine and prednisone are administered simultaneously, sequentially or separately.<p>[DC]</p> 18. The method of claim 1, wherein the patient is further treated with radiotherapy.",
                     "source":"<p>Source:</p> US9603927B2, Janssen Bio. Company: Darzalex® Product"
                  },
                  {  
                     "name":"Sub-population (Ethnicity, Mutations, Weight, Gender?)",
                     "color":"red",
                     "children":[  
                        {  
                           "name":"Absence of Condition XYZ",
                           "color":"red",
                           "claimReason":"“… who does not have rheumatoid arthritis or cancer …”",
                           "indClaim":"<p>[IC]</p> 2. A method of treating vasculitis in a human who does not have rheumatoid arthritis or cancer comprising: <p>(a)</p> administering to the human more than one intravenous dose of a therapeutically effective amount of rituximab; and <p>(b)</p> administering to the human glucocorticosteroid.",
                           "depClaim":"<p>[DC]</p> 3. The method of claim 2 wherein the glucocorticosteroid is prednisone, methylprednisolone, or dexamethasone.",
                           "source":"<p>Source:</p> US8545843B2, Genentech Company: Rituxan® Product"
                        },
                        {  
                           "name":"Age",
                           "color":"red",
                           "claimReason":"“… wherein the patient is >60 years old …”",
                           "indClaim":"<p>[IC]</p> 1. A method of treating a patient with diffuse large cell lymphoma comprising administering anti- CD20 antibody and chemotherapy to the patient, wherein the patient is >60 years old, wherein the chemotherapy comprises CHOP (cyclophosphamide, hydroxydaunorubicin/doxorubicin, vincristine, and prednisone/prednisolone), and wherein the anti-CD20 antibody is administered to the patient in combination with stem cell transplantation regimen.",
                           "depClaim":"<p>[DC]</p> 2. The method of claim 1, wherein the antibody comprises a chimeric anti-CD20 antibody.3. The method of claim 2, wherein the antibody comprises rituximab.<p>[DC]</p> 4. The method of claim 1, wherein the lymphoma is accompanied by bone marrow involvement.",
                           "source":"<p>Source:</p> US8821873B2, Genentech Company: Rituxan® Product"
                        }
                     ]
                  },
                  {  
                     "name":"Second Line Treatment",
                     "color":"red",
                     "claimReason":"“… has failed NSAID therapy …”",
                     "indClaim":"<p>[IC]</p> 1. A method of treatment of psoriasis in a patient with moderate to severe active psoriatic arthritis (PsA), comprising subcutaneously administering to said patient 40 mg adalimumab every other week, wherein said patient has 3 swollen and 3 tender joints prior to the treatment and has failed NSAID therapy, and wherein said patient achieves a 90% reduction of the Psoriasis Area and Severity Index Score (PASI 90) at week 24 of the treatment.",
                     "depClaim":"<p>[DC]</p> 2. The method of claim 1, wherein said patient has psoriasis in <3% body surface area prior to the treatment.<p>[DC]</p> 3. The method of claim 1, wherein said patient has psoriasis in 3% body surface area prior to the treatment.",
                     "source":"<p>Source:</p> US8906372B2, Abott Biotech Company: Humira® Product"
                  },
                  {  
                     "name":" Prerequisites",
                     "color":"red",
                     "claimReason":"“… who does not have rheumatoid arthritis or cancer …”",
                     "indClaim":"<p>[IC]</p> 2. A method of treating vasculitis in a human who does not have rheumatoid arthritis or cancer comprising: <p>(a)</p> administering to the human more than one intravenous dose of a therapeutically effective amount of rituximab; and <p>(b)</p> administering to the human glucocorticosteroid.",
                     "depClaim":"<p>[DC]</p> 3. The method of claim 2 wherein the glucocorticosteroid is prednisone, methylprednisolone, or dexamethasone.",
                     "source":"<p>Source:</p> US8545843B2, Genentech Company: Rituxan® Product"
                  },
                  {  
                     "name":"W/ Formulation",
                     "color":"red",
                     "claimReason":"“… method treatment, comprising administering to a patient with Crohn's disease a therapeutic amount of a stable, aqueous pharmaceutical formulation comprising from about 20 mg/ml to about 150 mg/ml of natalizumab …”",
                     "indClaim":"<p>[IC]</p> 9. A method treatment, comprising administering to a patient with Crohn's disease a therapeutic amount of a stable, aqueous pharmaceutical formulation comprising from about 20 mg/ml to about 150 mg/ml of natalizumab, about 10 mM phosphate buffer, about 140 mM sodium chloride, and polysorbate 80 present in an amount of about 0.001% to 2% (w/v), wherein the Crohn's disease is treated by administration of the stable, aqueous pharmaceutical formulation.",
                     "depClaim":"<p>[DC]</p> 10. The method of claim 9, wherein the pharmaceutical formulation is administered to the patient by intravenous administration.<p>[DC]</p> 11. The method of 10, wherein the pharmaceutical formulation is administered to the patient over a series of treatments.<p>[DC]</p> 12. The method of claim 9, wherein natalizumab is present in an amount of about 20 mg/mL.<p>[DC]</p> 13. The method of claim 9, wherein the polysorbate 80 is present an amount of about 0.02% (w/v).<p>[DC]</p> 14. The method of claim 9, wherein the formulation has a pH of about 3.0 to about 7.0.<p>[DC]</p> 15. The method of claim 14, wherein the pH is about 5.5 to about 6.5.<p>[DC]</p> 16. The method of claim 15, wherein the pH is about 6.0 ±0.5.<p>[DC]</p> 18. The method of claim 9, wherein the pharmaceutical formulation is administered to the patient by subcutaneous administration.",
                     "source":"<p>Source:</p> US8815236B2, Biogen Company: Tysabri® Product"
                  },
                  {  
                     "name":"Treating Signs & Symptons",
                     "color":"red",
                     "claimReason":"“… method of reducing signs and symptoms in a patient with …”",
                     "indClaim":"<p>[IC]</p> 1. A method of reducing signs and symptoms in a patient with moderately to severely active rheumatoid arthritis, comprising: administering to said patient, in combination with methotrexate, a human anti-TNF antibody, wherein the human anti-TNF antibody is administered subcutaneously in a total body dose of 40 mg once every 13-15 days, and wherein the anti-TNF antibody comprises an IgG1 heavy chain constant region; a variable light (“V L”) chain region comprising a CDR1 having the amino acid sequence of SEQ ID NO:7, a CDR2 having the amino acid sequence of SEQ ID NO:5, and a CDR3 having the amino acid sequence of SEQ ID NO:3; and a variable heavy (“VH”) chain region comprising a CDR1 having the amino acid sequence of SEQ ID NO:8, a CDR2 having the amino acid sequence of SEQ ID NO:6 and a CDR3 having the amino acid sequence of SEQ ID NO:4.",
                     "depClaim":"<p>[DC]</p> 2. The method of claim 1, wherein the VL chain region of the anti-TNF antibody has the amino acid sequence of SEQ ID NO:1 and the VH chain region of the anti-TNF antibody has the amino acid sequence of SEQ ID NO:2.<p>[DC]</p> 3. The method of claim 1, wherein the dosage is administered from a 40 mg dosage unit form.<p>[DC]</p> 4. The method of claim 3, wherein the VL chain region of the anti-TNF antibody has the amino acid sequence of SEQ ID NO:1 and the VH chain region of the anti-TNF antibody has the amino acid sequence of SEQ ID NO:2.",
                     "source":"<p>Source:</p> US9017680B2, Abott Biotech Company: Humira® Product"
                  },
                  {  
                     "name":"Treatment with Side Effects",
                     "color":"red",
                     "claimReason":"“… wherein the patient has a grade III hypertensive event resulting from the bevacizumab administration, the method further comprising administering to the patient an antihypertensive agent in an amount sufficient to manage the grade III hypertensive event while continuing to treat the patient with bevacizumab …”",
                     "indClaim":"<p>[IC]</p> 1. A method of treating cancer in a patient comprising administering to the patient an effective amount of bevacizumab, wherein the patient has a grade III hypertensive event resulting from the bevacizumab administration, the method further comprising administering to the patient an antihypertensive agent in an amount sufficient to manage the grade III hypertensive event while continuing to treat the patient with bevacizumab, the continued bevacizumab treatment being carried out without altering the dosage regimen.",
                     "depClaim":"<p>[DC]</p> 2. The method of claim 1, wherein the method further comprises administering one or more chemotherapeutic agents.<p>[DC]</p> 3. The method of claim 2, wherein the one or more chemotherapeutic agents is one or more of an alkylating agent, antimetabolite, pyrimidine analog, vinca alkyloid, epipodophyllotoxin, antibiotic, topoisomerase inhibitor, interferon, platinum coordination complex, or taxoid.<p>[DC]</p> 4. The method of claim 3, wherein the one or more chemotherapeutic agents is one or more of a pyrimidine analog, 5-fluorouracil (5-FU), leucovorin, irinotecan, paclitaxel, oxaliplatin, carboplatin, cisplatin, doxorubicin, topotecan, or interferon-alpha.<p>[DC]</p> 5. The method of claim 4, wherein the one or more chemotherapeutic agents is one or more of 5-FU, leucovorin, irinotecan, or oxaliplatin.<p>[DC]</p> 7. The method of claim 2, wherein the cancer is colorectal cancer, rectal cancer, glioblastoma, non-small cell lung cancer, cervical cancer, peritoneum cancer, renal cancer, ovarian cancer, or mesothelioma.<p>[DC]</p> 8. The method of claim 5, wherein the cancer is metastatic colorectal cancer.<p>[DC]</p> 9. The method of claim 6, wherein the cancer is metastatic colorectal cancer.<p>[DC]</p> 10. The method of claim 4, wherein the cancer is metastatic non-small cell lung cancer.<p>[DC]</p> 11. The method of claim 4, wherein the cancer is metastatic cervical cancer.<p>[DC]</p> 12. The method of claim 4, wherein the cancer is metastatic ovarian cancer or metastatic peritoneum cancer.<p>[DC]</p> 13. The method of claim 4, wherein the cancer is metastatic renal cancer.<p>[DC]</p> 14. The method of claim 1, wherein the cancer is glioblastoma.<p>[DC]</p> 15. The method of claim 1, wherein the bevacizumab is administered to the patient bi-weekly at about 10 mg/kg.<p>[DC]</p> 16. The method of claim 4, wherein the patient does not have clinically significant cardiovascular disease prior to the bevacizumab administration.<p>[DC]</p> 17. The method of claim 8, wherein one of the one or more chemotherapeutic agents is 5-FU.<p>[DC]</p> 18. The method of claim 1, wherein the bevacizumab is administered to the patient bi-weekly at about 5 mg/kg.",
                     "source":"<p>Source:</p> US9795672B2, Genentech Company: Avastin® Product"
                  },
                  {  
                     "name":"Improving effectiveness of Treatment",
                     "color":"red",
                     "children":[  
                        {  
                           "name":"Improving Succes Rate",
                           "color":"red",
                           "claimReason":"“… method for increasing likelihood of effectiveness of breast cancer treatment with humanized anti-ErbB2 antibody huMAb4D5-8, which method comprises administering …”",
                           "indClaim":"<p>[IC]</p> 1. A method for increasing likelihood of effectiveness of breast cancer treatment with humanized anti-ErbB2 antibody huMAb4D5-8, which method comprises administering a cancer treating dose of said antibody to a human subject diagnosed with breast cancer, wherein an erbB2 gene amplification in breast cancer cells in a tissue sample from the subject has been detected, and wherein the breast cancer cells from the human subject have been found to have a 0 or 1+ score of ErbB2 protein expression by immunohistochemistry.",
                           "depClaim":"<p>[DC]</p> 2. The method according to claim 1, wherein the breast cancer cells from the human subject have been found to have a 0 or 1+ score of ErbB2 protein expression by immunohistochemistry on a formaldehyde-fixed tissue sample.<p>[DC]</p> 3. The method according to claim 1 wherein the erbB2 gene amplification is detected by detecting fluorescence of a fluorescent-labeled nucleic acid probe hybridized to the gene.<p>[DC]</p> 4. The method according to claim 1, which further comprises administering a cancer treating dose of a chemotherapeutic drug.<p>[DC]</p> 5. The method according to claim 4, wherein the chemotherapeutic drug is a taxoid.<p>[DC]</p> 6. The method according to claim 1 wherein the likelihood of effectiveness increases by about 30%.",
                           "source":"<p>Source:</p> US7993834B2, Genentech Company: Herceptin® Product"
                        },
                        {  
                           "name":"Preventing Adverce Events",
                           "color":"red",
                           "claimReason":"“… method for ameliorating or preventing an adverse effect mediated by the administration of a CD19×CD3 bispecific antibody …”",
                           "indClaim":"<p>[IC]</p> 32. A method for ameliorating or preventing an adverse effect mediated by the administration of a CD19×CD3 bispecific antibody to a human patient having a B:T cell ratio of about 1:5 or lower, said method comprising: <p>(a)</p> determining the ratio of total B cells to total T cells in a peripheral blood sample from said human patient to identify patients at risk of developing an adverse effect; <p>(b)</p> identifying said human patient as having an increased risk of potential adverse effects when the ratio of B:T cells is about 1:5 or less before treatment; <p>(c)</p> administering a first dose of said antibody for a first period of time to said patient identified in (b), and consecutively; <p>(d)</p> administering a second dose of said antibody for a second period of time; wherein said second dose exceeds said first dose, and wherein said CD19×CD3 bispecific antibody is MT103 (Blinatumomab).",
                           "depClaim":"<p>[DC]</p> 33. The method of claim 32, wherein said adverse effect is characterized by a neurological reaction.<p>[DC]</p> 34. The method of claim 33, wherein said neurological reaction is one or more selected from the group consisting of: confusion, ataxia, disorientation, dysphasia, aphasia, speech impairment, cerebellar symptoms, tremor, apraxia, seizure, grand mal convulsion, palsy, and balance disorder.",
                           "source":"<p>Source:</p> US8840888B2, Amgen Company: Blincyto® Product"
                        }
                     ]
                  }
               ]
            },
            {  
               "name":"Mechanism of Action",
               "color":"red",
               "claimReason":"“… method for increasing an immune response to an antigen in a subject …”",
               "indClaim":"<p>[IC]</p> 1. A method for increasing an immune response to an antigen in a subject, the method comprising administering to the subject an anti-CTLA-4 antibody or antigen-binding portion thereof, wherein the antibody or antigen-binding portion thereof comprises a heavy chain variable region that comprises CDR1, CDR2, and CDR3 domains; and a light chain variable region that comprises CDR1, CDR2, and CDR3 domains, wherein the heavy chain variable region and light chain variable region CDR3 domains are selected from the group consisting of: <p>(a)</p> a heavy chain variable region CDR3 comprising amino acids having the sequence set forth in SEQ ID NO:37; and a light chain variable region CDR3 comprising amino acids having the sequence set forth in SEQ ID NO:35; and <p>(b)</p> a heavy chain variable region CDR3 comprising amino acids having the sequence set forth in SEQ ID NO:38; and a light chain variable region CDR3 comprising amino acids having the sequence set forth in SEQ ID NO:36; and binds to human CTLA-4 with a binding affinity of about 10 8 M1 or greater.",
               "depClaim":"<p>[DC]</p> 2. The method of claim 1, wherein the antibody or antigen-binding portion thereof comprises: <p>(a)</p> a heavy chain variable region comprising CDR3 and CDR2 sequences set forth in SEQ ID NOs:37 and 32, respectively; and a light chain variable region comprising CDR3 and CDR2 sequences set forth in SEQ ID NOs:35 and 29, respectively; <p>(b)</p> a heavy chain variable region comprising CDR3 and CDR2 sequences set forth in SEQ ID NOs: 37 and 33, respectively; and a light chain variable region comprising CDR3 and CDR2 sequences set forth in SEQ ID NOs: 35 and 30, respectively; or <p>(c)</p> a heavy chain variable region comprising CDR3 and CDR2 sequences set forth in SEQ ID NOs:38 and 34, respectively; and a light chain variable region comprising CDR3 and CDR2 sequences set forth in SEQ ID NOs:36 and 31, respectively.<p>[DC]</p> 3. The method of claim 2, wherein the antibody or antigen-binding portion thereof comprises: <p>(a)</p> a heavy chain variable region comprising CDR3, CDR2 and CDR1 sequences set forth in SEQ ID NOs:37, 32 and 27, respectively; and a light chain variable region comprising CDR3, CDR2 and CDR1 sequences set forth in SEQ ID NOs:35, 29 and 24, respectively; <p>(b)</p> a heavy chain variable region comprising CDR3, CDR2 and CDR1 sequences set forth in SEQ ID NOs:37, 33 and 27, respectively; and a light chain variable region comprising CDR3, CDR2 and CDR1 sequences set forth in SEQ ID NOs:35, 30 and 25, respectively; or <p>(c)</p> a heavy chain variable region comprising CDR3, CDR2 and CDR1 comprising sequences set forth in SEQ ID NOs:38, 34 and 28, respectively; and a light chain variable region comprising CDR3, CDR2 and CDR1 sequences set forth in SEQ ID NOs:36, 31 and 26, respectively.<p>[DC]</p> 4. The method of claim 1, wherein the antibody or antigen-binding portion thereof comprises: <p>(a)</p> a heavy chain variable region derived from a human VH 3-30.3 gene; and <p>(b)</p> a light chain variable region derived from a human VK A-27 gene.<p>[DC]</p> 5. The method of claim 1, wherein the antibody or antigen-binding portion thereof comprises: <p>(a)</p> a heavy chain variable region derived from a human VH 3-33 gene; and <p>(b)</p> a light chain variable region derived from a human VK L-15 gene.<p>[DC]</p> 6. The method of claim 4, wherein the antibody or antigen-binding portion thereof comprises a heavy chain variable region CDR3 sequence set forth in SEQ ID NO: 37, and a light chain variable region CDR3 sequence set forth in SEQ ID NO: 35.<p>[DC]</p> 7. The method of claim 5, wherein the antibody or antigen-binding portion thereof comprises a heavy chain variable region CDR3 sequence set forth in SEQ ID NO: 38, and a light chain variable region CDR3 sequence set forth in SEQ ID NO: 36.<p>[DC]</p> 8. The method of claim 1, wherein the antibody or antigen-binding portion thereof comprises at least one heavy chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOS: 17, 19 and 23.<p>[DC]</p> 9. The method of claim 1, wherein the antibody or antigen-binding portion thereof comprises at least one light chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOS: 7, 9 and 13.<p>[DC]</p> 10. The method of claim 1, wherein the antibody or antigen-binding portion thereof comprises a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 17 and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 7.<p>[DC]</p> 11. The method of claim 1, wherein the antibody or antigen-binding portion thereof comprises a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 19 and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 9.<p>[DC]</p> 12. The method of claim 1, wherein the antibody or antigen-binding portion thereof comprises a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 23 and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 13.<p>[DC]</p> 13. The method of claim 1, wherein the antibody or antigen-binding portion thereof comprises: <p>(a)</p> a heavy chain variable region comprising CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NOS: 27, 32 and 37, respectively; and <p>(b)</p> a light chain variable region comprising CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NOS: 24, 29 and 35, respectively.<p>[DC]</p> 14. The method of claim 1, wherein the antibody or antigen-binding portion thereof comprises: <p>(a)</p> a heavy chain variable region comprising CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NOS: 27, 33 and 37, respectively; and <p>(b)</p> a light chain variable region comprising CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NOS: 25, 30 and 35, respectively.<p>[DC]</p> 15. The method of claim 1, wherein the antibody or antigen-binding portion thereof comprises: <p>(a)</p> a heavy chain variable region comprising CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NOS: 28, 34 and 38, respectively; and <p>(b)</p> a light chain variable region comprising CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NOS: 26, 31 and 36, respectively.",
               "source":"<p>Source:</p> US8784815B2, Ono Pharma (BMS) Company: Yervoy® Product"
            },
            {  
               "name":"Depletion of B Cells",
               "color":"red",
               "claimReason":"“… method of depleting peripheral blood B cells in a human host …”",
               "indClaim":"<p>[IC]</p> 1. A method of depleting peripheral blood B cells in a human host comprising administering to the host an immunologically active chimeric anti-CD20 antibody in an amount effective to deplete peripheral blood B cells in the host, wherein the antibody comprises a light chain variable region comprising amino acid residues 23 to 128 of SEQ ID NO: 4, a human immunoglobulin light chain kappa constant region, a heavy chain variable region comprising amino acid residues 20 to 140 of SEQ ID NO: 6, and a human immunoglobulin heavy chain gamma 1 constant region.",
               "depClaim":"<p>[DC]</p> 2. The method of claim 1 wherein the antibody is administered to the host in four separate infusions of 375 mg/m2 per infusion.<p>[DC]</p> 3. The method of claim 1 wherein the administration of the antibody causes peripheral blood B cells in the host to be depleted for a period in excess of 2 weeks.<p>[DC]</p> 4. A method for depleting peripheral blood B cells in a host in need of such treatment comprising administering an amount of an immunologically active chimeric anti-CD20 sufficient to induce B cell depletion, wherein the antibody comprises a light chain variable region comprising the amino acid sequence shown as residues 23 to 128 of SEQ ID NO: 4 and a heavy chain variable region comprising the amino acid sequence shown as residues 20 to 140 of SEQ ID NO: 6, and the amount of antibody administered comprises four separate infusions of 375 mg/m2.",
               "source":"<p>Source:</p> US7744877B2, Genentech Company: Rituxan® Product"
            },
            {  
               "name":"Safety",
               "color":"red",
               "claimReason":"“… method of reducing the incidence of an adverse event induced by a therapeutic dose …”",
               "indClaim":"<p>[IC]</p> 24. A method of reducing the incidence of an adverse event induced by a therapeutic dose of an anti-CTLA-4 monoclonal antibody or an antigen-binding portion thereof in treating a hyperproliferative disease, in a subject in need thereof comprising administering <p>(i)</p> a dose of an anti-PD-1 monoclonal antibody or an antigen-binding portion thereof and <p>(ii)</p> a subtherapeutic dose of the anti-CTLA-4 monoclonal antibody or an antigen-binding portion thereof to the subject, wherein the subject exhibits a reduction in the adverse event after the administration.",
               "depClaim":"<p>[DC]</p> 25. The method of claim 24, wherein the adverse event induced by the anti-CTLA-4 monoclonal antibody or an antigen-binding portion thereof comprises colitis, diarrhea, rash, pruritis, esophagitis, duodenitis, ileitis, or any combination thereof.<p>[DC]</p> 26. The method of claim 24, further comprising administering a non-absorbable steroid to the subject.<p>[DC]</p> 27. The method of claim 26, wherein the non-absorbable steroid is a corticosteroid.<p>[DC]</p> 28. The method of claim 26, wherein the non-absorbable steroid is administered prior to the administration of the anti-PD-1 antibody or antigen-binding portion thereof or the anti-CTLA-4 antibody or antigen-binding portion thereof.<p>[DC]</p> 29. The method of claim 5 or 17, wherein the cancer is selected from melanoma, lung cancer, renal cancer, prostate cancer, breast cancer, colorectal cancer, and fibrosarcoma.<p>[DC]</p> 30. The method of claim 5 or 17, wherein the cancer is bone cancer, pancreatic cancer, skin cancer, cancer of the head or neck, cutaneous or intraocular malignant melanoma, uterine cancer, ovarian cancer, rectal cancer, cancer of the anal region, stomach cancer, testicular cancer, uterine cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, Hodgkin's Disease, non-Hodgkin's lymphoma, cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma of soft tissue, cancer of the urethra, cancer of the penis, chronic or acute leukemia, acute myeloid leukemia, chronic myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, solid tumors of childhood, lymphocytic lymphoma, cancer of the bladder, cancer of the kidney or ureter, carcinoma of the renal pelvis, neoplasm of the central nervous system (CNS), primary CNS lymphoma, tumor angiogenesis, spinal axis tumor, brain stem glioma, pituitary adenoma, Kaposi's sarcoma, epidermoid cancer, squamous cell cancer, T-cell lymphoma, environmentally induced cancers including those induced by asbestos, and combinations of said cancers.<p>[DC]</p> 31. The method of any one of claims 5, 17, and 24, wherein the combination of the anti-PD-1 antibody or antigen-binding portion thereof and the anti-CTLA-4 antibody or antigen-binding portion thereof is administered concurrently as a single composition or as separate compositions.<p>[DC]</p> 32. The method of any one of claims 5, 17, and 24, wherein the combination of the anti-PD-1 antibody or antigen-binding portion thereof and the anti-CTLA-4 antibody or antigen-binding portion thereof is administered sequentially.<p>[DC]</p> 33. The method of any one of claims 5, 17, and 24, wherein the anti-PD-1 antibody or antigenbinding portion thereof cross-competes for binding to human PD-1 with a reference antibody comprising: <p>(a)</p> a heavy chain CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 15; a heavy chain CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 22; a heavy chain CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 29; a light chain CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 36; a light chain CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 43; and a light chain CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 50; <p>(b)</p> a heavy chain CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 16; a heavy chain CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 23; a heavy chain CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 30; a light chain CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 37; a light chain CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 44; and a light chain CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 51; <p>(c)</p> a heavy chain CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 17; a heavy chain CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 24; a heavy chain CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 31; a light chain CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 38; a light chain CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 45; and a light chain CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 52; <p>(d)</p> a heavy chain CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 18; a heavy chain CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 25; a heavy chain CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 32; a light chain CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 39; a light chain CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 46; and a light chain CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 53; <p>(e)</p> a heavy chain CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 19; a heavy chain CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 26; a heavy chain CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 33; a light chain CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 40; a light chain CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 47; and a light chain CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 54; <p>(f)</p> a heavy chain CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 20; a heavy chain CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 27; a heavy chain CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 34; a light chain CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 41; a light chain CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 48; and a light chain CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 55; or <p>(g)</p> a heavy chain CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 21; a heavy chain CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 28; a heavy chain CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 35; a light chain CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 42; a light chain CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 49; and a light chain CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 56.<p>[DC]</p> 34. The method of claim 33, wherein the reference antibody comprises: <p>(a)</p> a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 1 and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 8; <p>(b)</p> a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 2 and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 9; <p>(c)</p> a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 3 and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 10; <p>(d)</p> a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 4 and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 11; <p>(e)</p> a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 5 and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 12; <p>(f)</p> a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 6 and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 13; or <p>(g)</p> a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 7 and a light chain variable region comprising the amino acid sequence set forth in SEO ID NO: 14.<p>[DC]</p> 35. The method of claim 34, wherein the reference antibody comprises a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 4 and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 11.<p>[DC]</p> 36. The method of claim 34, wherein the anti-PD-1 antibody or antigen-binding portion thereof exhibits one or more of the following properties: <p>(i)</p> the anti-PD-1 antibody or antigen-binding portion thereof binds to human PD-1 with a K D of 1×108 M or less, wherein the KD is measured by surface plasmon resonance (Biacore) analysis; <p>(ii)</p> the anti-PD-1 antibody or antigen-binding portion thereof binds to human PD-1 with an on rate (k on) of about 0.76×105 I/Ms or more, wherein the on rate (kon) is measured by surface plasmon resonance (Biacore) analysis; and <p>(iii)</p> the anti-PD-1 antibody or antigen-binding portion thereof binds to human PD-1 with an off rate (k off) of about 4.5×104 l/s or less, wherein the off rate (koff) is measured by surface plasmon resonance (Biacore) analysis.<p>[DC]</p> 37. The method of claim 36, wherein the anti-PD-1 antibody or antigen-binding portion thereof binds to human PD-1 with a KD of 5×109 M or less, wherein the KD is measured by surface plasmon resonance (Biacore) analysis.<p>[DC]</p> 38. The method of claim 37, wherein the anti-PD-1 antibody or antigen-binding portion thereof binds to human PD-1 with a KD of 1×109 M or less, wherein the KD is measured by surface plasmon resonance (Biacore) analysis.<p>[DC]</p> 39. The method of claim 36, wherein the anti-PD-1 antibody or antigen-binding portion thereof has the following properties: <p>(i)</p> the anti-PD-1 antibody or antigen-binding portion thereof binds to human PD-1 with a K D of 1×109 M or less, wherein the KD is measured by surface plasmon resonance (Biacore) analysis; <p>(ii)</p> the anti-PD-1 antibody or antigen-binding portion thereof binds to human PD-1 with an on rate (k on) of about 0.76×105 I/Ms or more, wherein the on rate (kon) is measured by surface plasmon resonance (Biacore) analysis; and <p>(iii)</p> the anti-PD-1 antibody or antigen-binding portion thereof binds to human PD-1 with an off rate (k off) of about 4.5×104 l/s or less, wherein the off rate (koff) is measured by surface plasmon resonance (Biacore) analysis.<p>[DC]</p> 40. The method of any one of claims 5, 17, and 24, wherein the anti-PD-1 antibody or antigenbinding portion thereof comprises: <p>(a)</p> a heavy chain CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 15; a heavy chain CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 22; a heavy chain CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 29; a light chain CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 36; a light chain CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 43; and a light chain CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 50; <p>(b)</p> a heavy chain CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 16; a heavy chain CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 23; a heavy chain CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 30; a light chain CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 37; a light chain CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 44; and a light chain CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 51; <p>(c)</p> a heavy chain CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 17; a heavy chain CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 24; a heavy chain CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 31; a light chain CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 38; a light chain CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 45; and a light chain CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 52; <p>(d)</p> a heavy chain CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 18; a heavy chain CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 25; a heavy chain CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 32; a light chain CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 39; a light chain CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 46; and a light chain CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 53; <p>(e)</p> a heavy chain CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 19; a heavy chain CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 26; a heavy chain CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 33; a light chain CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 40; a light chain CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 47; and a light chain CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 54; <p>(f)</p> a heavy chain CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 20; a heavy chain CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 27; a heavy chain CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 34; a light chain CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 41; a light chain CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 48; and a light chain CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 55; or <p>(g)</p> a heavy chain CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 21; a heavy chain CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 28; a heavy chain CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 35; a light chain CDR1 comprising amino acids having the sequence set forth in SEQ ID NO: 42; a light chain CDR2 comprising amino acids having the sequence set forth in SEQ ID NO: 49; and a light chain CDR3 comprising amino acids having the sequence set forth in SEQ ID NO: 56.<p>[DC]</p> 41. The method of claim 40, wherein the anti-PD-1 antibody or antigen-binding portion thereof comprises: <p>(a)</p> a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 1 and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 8; <p>(b)</p> a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 2 and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 9; <p>(c)</p> a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 3 and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 10; <p>(d)</p> a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 4 and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 11; <p>(e)</p> a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 5 and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 12; <p>(f)</p> a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 6 and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 13; or <p>(g)</p> a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 7 and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 14.<p>[DC]</p> 42. The method of claim 41, wherein the anti-PD-1 antibody or antigen-binding portion thereof comprises a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 4 and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 11.<p>[DC]</p> 43. The method of claim 41 wherein the anti-PD-1 antibody or antigen-binding portion thereof has one or more properties: <p>(i)</p> the anti-PD-1 antibody or antigen-binding portion thereof binds to human PD-1 with a K D of 1×108 M or less, wherein the KD is measured by surface plasmon resonance (Biacore) analysis; <p>(ii)</p> the anti-PD-1 antibody or antigen-binding portion thereof binds to human PD-1 with an on rate (k on) of about 0.76×105 I/Ms or more, wherein the on rate (kon) is measured by surface plasmon resonance (Biacore) analysis; and <p>(iii)</p> the anti-PD-1 antibody or antigen-binding portion thereof binds to human PD-1 with an off rate (k off) of about 4.5×104 l/s or less, wherein the off rate (koff) is measured by surface plasmon resonance (Biacore) analysis.<p>[DC]</p> 44. The method of claim 43, wherein the anti-PD-1 antibody or antigen-binding portion thereof binds to human PD-1 with a KD of 5×109 M or less, wherein the KD is measured by surface plasmon resonance (Biacore) analysis.<p>[DC]</p> 45. The method of claim 44, wherein the anti-PD-1 antibody or antigen-binding portion thereof binds to human PD-1 with a KD of 1×109 M or less, wherein the KD is measured by surface plasmon resonance (Biacore) analysis.<p>[DC]</p> 46. The method of claim 43, wherein the anti-PD-1 antibody or antigen-binding portion thereof has the following properties: <p>(i)</p> the anti-PD-1 antibody or antigen-binding portion thereof binds to human PD-1 with a K D of 1×109 M or less, wherein the KD is measured by surface plasmon resonance (Biacore) analysis; <p>(ii)</p> the anti-PD-1 antibody or antigen-binding portion thereof binds to human PD-1 with an on rate (k on) of about 0.76×105 I/Ms or more, wherein the on rate (kon) is measured by surface plasmon resonance (Biacore) analysis; and <p>(iii)</p> the anti-PD-1 antibody or antigen-binding portion thereof binds to human PD-1 with an off rate (k off) of about 4.5×104 l/s or less, wherein the off rate (koff) is measured by surface plasmon resonance (Biacore) analysis.<p>[DC]</p> 47. The method of claim 40, wherein the anti-PD-1 antibody or antigen-binding portion thereof comprises a heavy chain variable region and a light chain variable region, which comprises EIVLTQSPATLSLSPGERATLSC (SEQ ID NO: 75) containing one amino acid mutation.<p>[DC]</p> 48. The method of any one of claims 5, 17, and 24, wherein the anti-PD-1 antibody or antigenbinding portion thereof comprises a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 4 and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 11.<p>[DC]</p> 49. The method of any one of claims 5, 17, and 24, wherein the anti-CTLA-4 antibody is human monoclonal antibody 10D1.",
               "source":"<p>Source:</p> US9358289B2, Ono Pharma (BMS) Company: Opdivo® Product"
            },
            {  
               "name":"Treatment by which XYZ is achieved",
               "color":"red",
               "children":[  
                  {  
                     "name":"In Vivo",
                     "color":"red"
                  },
                  {  
                     "name":"In Vitro",
                     "color":"red"
                  }
               ]
            },
            {  
               "name":"Regimen",
               "color":"red",
               "children":[  
                  {  
                     "name":"Constant Dose",
                     "color":"red"
                  },
                  {  
                     "name":"Multi-variable Dose",
                     "color":"red"
                  },
                  {  
                     "name":"Dose Dependent on XYZ",
                     "color":"red"
                  },
                  {  
                     "name":"Administration Frequency",
                     "color":"red"
                  }
               ]
            },
            {  
               "name":"Administration in Combination",
               "color":"red"
            },
            {  
               "name":"Inhibiting XYZ",
               "color":"red",
               "children":[  
                  {  
                     "name":"In Vivo",
                     "color":"red"
                  },
                  {  
                     "name":"In Vitro",
                     "color":"red"
                  }
               ]
            },
            {  
               "name":"Vaccine",
               "color":"red"
            }
         ]
      },
      {  
         "name":"Prevention",
         "color":"orange"
      },
      {  
         "name":"Diagnostics",
         "color":"aqua",
         "children":[  
            {  
               "name":"Detecting (e.g. TNF)",
               "color":"aqua",
               "children":[  
                  {  
                     "name":"In Vivo",
                     "color":"aqua"
                  },
                  {  
                     "name":"In Vitro",
                     "color":"aqua"
                  }
               ]
            }
         ]
      },
      {  
         "name":"Competition",
         "color":"navy",
         "children":[  
            {  
               "name":"Cross Competition",
               "color":"navy"
            },
            {  
               "name":"Affinity Competition",
               "color":"navy"
            }
         ]
      },
      {  
         "name":"Drug Delivery Devices",
         "color":"fuchsia",
         "children":[  
            {  
               "name":"Administration Device (General & Treatment specific)",
               "color":"fuchsia",
               "children":[  
                  {  
                     "name":"Components",
                     "color":"fuchsia"
                  },
                  {  
                     "name":"Operation",
                     "color":"fuchsia"
                  }
               ]
            },
            {  
               "name":"Training Device",
               "color":"fuchsia"
            }
         ]
      },
      {  
         "name":"Article of Manufacture",
         "color":"olive"
      },
      {  
         "name":"Methodology",
         "color":"teal",
         "children":[  
            {  
               "name":"Biomarkers",
               "color":"teal",
               "children":[  
                  {  
                     "name":"Efficacy of Treatment",
                     "color":"teal"
                  },
                  {  
                     "name":"Responsiveness",
                     "color":"teal"
                  },
                  {  
                     "name":"Monitoring of XYZ",
                     "color":"teal"
                  },
                  {  
                     "name":"Safety",
                     "color":"teal"
                  }
               ]
            },
            {  
               "name":"Production",
               "color":"teal",
               "children":[  
                  {  
                     "name":"General Method",
                     "color":"teal"
                  },
                  {  
                     "name":"Batch Method",
                     "color":"teal"
                  },
                  {  
                     "name":"Condition XYZ Specific",
                     "color":"teal"
                  },
                  {  
                     "name":"Concentrating",
                     "color":"teal"
                  },
                  {  
                     "name":"Disulfide bond",
                     "color":"teal"
                  },
                  {  
                     "name":"Humanisation",
                     "color":"teal"
                  }
               ]
            },
            {  
               "name":"Modification",
               "color":"teal",
               "children":[  
                  {  
                     "name":"Reducing Impurities",
                     "color":"teal"
                  },
                  {  
                     "name":"Purificiation",
                     "color":"teal",
                     "children":[  
                        {  
                           "name":"Assay for determining functionality",
                           "color":"teal"
                        },
                        {  
                           "name":"Various Methodologies",
                           "color":"teal"
                        }
                     ]
                  },
                  {  
                     "name":"Galactosylation",
                     "color":"teal"
                  },
                  {  
                     "name":"PH",
                     "color":"teal"
                  },
                  {  
                     "name":"Viscosity",
                     "color":"teal"
                  }
               ]
            },
            {  
               "name":"Host Cells",
               "color":"teal",
               "children":[  
                  {  
                     "name":"Enhancing Protein Expression",
                     "color":"teal"
                  },
                  {  
                     "name":"Prolonging Viability",
                     "color":"teal"
                  },
                  {  
                     "name":"Reducing Production of Undesirable XYZ",
                     "color":"teal"
                  },
                  {  
                     "name":"Reducing Consumption of XYZ",
                     "color":"teal"
                  },
                  {  
                     "name":"Capable of Producing XYZ",
                     "color":"teal"
                  },
                  {  
                     "name":"Identified by Deposit  N",
                     "color":"teal"
                  },
                  {  
                     "name":"Glycoengineered",
                     "color":"teal"
                  }
               ]
            }
         ]
      },
      {  
         "name":"Media",
         "color":"maroon",
         "children":[  
            {  
               "name":"Cell Culture Medium",
               "color":"maroon"
            }
         ]
      },
      {  
         "name":"Sequence & Function",
         "color":"silver"
      }
   ]
}
